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ABSTRACT
Chlamydia trachomatis is an obligate intracellular bacterium that exhibits a
unique biphasic developmental cycle that can be disrupted by growth in the presence of
IFN-γ and β-lactams, giving rise to an abnormal growth state termed persistence.
Relatively little is known about the regulatory mechanisms that control temporal gene
expression during the developmental cycle or the control of persistence and reactivation.
Here we have examined the expression of a newly defined family of non-coding RNAs
(ncRNAs) that are differentially expressed during the developmental cycle and the
induction of persistence and reactivation (Using IFN-γ and Carbenicillin). Non-coding
RNAs were initially identified using an intergenic tiling microarray and were confirmed
by Northern blotting. A group of 10 ncRNAs were mapped and characterized and
compared to the previously described chlamydial ncRNAs (IhtA, pCHL antisense
transcripts). The 5’ and 3’ ends of the ncRNAs were determined using an RNA
circularization procedure. Promoter predictions indicated that all ncRNAs were
expressed from σ66 promoters and 9 ncRNAs contained non-templated 3’ poly-A or polyAG additions.
Expression of ncRNAs was studied by Northern blotting during i) the normal
developmental cycle, ii) IFN-γ-induced persistence, and iii) carbenicillin-induced
persistence. Differential temporal expression during the developmental cycle was seen
for all ncRNAs and distinct differences in expression were seen during IFN-γ and
carbenicillin-induced persistence and reactivation.
Two of the studied ncRNAs were cis acting antisense molecules (CTIG270 and
CTIG153). Expression of CTIG270 in a surrogate E. coli system along with its target
gene ftsI proved that it was an antisense RNA, and it effectively controlled ftsI
availability. A screening system was developed to determine the targets of potential
trans-acting ncRNAs. The screen was composed of two compatible plasmids, a high
copy effector plasmid expressing the ncRNA and a low/medium copy target plasmid
expressing chlamydial library. Target plasmid contained translational fusion between
chlamydial library and a positive/negative selection fusion system (ccdB/CAT
fusion/TEV protease). The selection process to identify potential targets for ncRNAs was
carried out over two stages. Stage one was to eliminate self ligated plasmids and non
translational fusions, in this phase, only CAT+ ccdB resistant cells survived
chloramphenicol selection i.e. cells representing true translational fusions survived
antibiotic selection. Plasmids enriched for by stage one selection were subjected to stage
two selection. In stage two ccdB sensitive cells were double transformed with both target
plasmid and effector plasmid. Only in instances when ncRNA inhibits translation of
ccdB would cells survive this selection. Stage two selection enriched for target(s) of
ncRNA under test. We show in details the construction of this screening system and its
functional aspect.
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CHAPTER 1. INTRODUCTION 1
1.1

CHLAMYDIA

The order Chlamydiales encompasses a large group of bacteria characterized by
their obligate growth in eukaryotic cells. The last decade has seen a rapid expansion of
the number of organisms within the order, including organisms from numerous animal
and environmental sources. This has led to the proposed division of the family
Chlamydiaceae to include two genera, Chlamydia and Chlamydophila and the inclusion
of non-Chlamydiaceae such as Simkaniaceae, Waddliaceae and Parachlamydiaceae
(Everett et al, 1999). The taxonomy of the Chlamydiales is controversial at this time and
many feel the genera divisions are unnecessary. I have chosen to use the terminology
described in Schachter et al, 2001 i.e. the use of a single genus, Chlamydia.
Chlamydiaceae are the etiological agents of many important human and animal
diseases. In humans, the genital serovars of Chlamydia trachomatis (C. trachomatis) are
the most prevalent cause of sexually transmitted disease worldwide (Gerbase et al, 1998),
while the ocular serovars result in blinding trachoma in developing countries (Schachter,
1978). Chlamydia pneumoniae (C. pneumoniae) is a widespread respiratory pathogen
(Kuo et al, 1995) and chronic infections are associated with an enhanced risk of
developing atherosclerotic (Saikku et al, 1988 and Kuo et al, 1993), cerebrovascular
(Balin et al, 1998), and chronic lung disease (Hahn et al, 1991). Pathogenic chlamydial
isolates have been characterized from a number of animal hosts including birds, cats,
rodents, cattle and pigs (e.g. Meijer, 2002).
Chlamydia alternates between two morphological forms, the elementary body
(EB) and the reticulate body (RB) (Moulder, 1991). EBs are extra-cellular, metabolically
inert forms, responsible for dissemination of infection by their ability to attach to and
invade susceptible cells. Upon infection, EBs are internalized in membrane bound
vacuoles termed inclusions. EBs differentiate into metabolically active forms, termed
RBs, and undergo repeated cycles of binary fission leading to secondary differentiation
back to EBs. The host cell then lyses, releasing EBs, which infect neighboring cells.
Under stressful growth conditions, imposed by immunological responses, antibiotics, or
nutrient deprivation, the developmental cycle is disrupted, resulting in the appearance of
large, aberrant RBs (reviewed in Hogan et al, 2004). This altered growth scheme appears
to be associated with continued expression of genes associated with DNA replication but
not with those genes involved with bacterial cell division (Belland et al, 2003a).
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Adapted by permission. Abdelrahman YM, Belland RJ (2005) The chlamydial developmental cycle.
FEMS Microbiol Rev 29: 949-959.
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1.2
1.2.1

THE DEVELOPMENTAL CYCLE

ELEMENTARY BODY

The term “elementary body” (EB) refers to the small (ca. 0.3 μm), round, electron
dense, infectious form of the organism (e.g. Matsumoto, 1973and Eb et al, 1976). EBs’
nucleotide is highly compacted due to the condensation of nuclear material by the
bacterial histone-like proteins HctA and HctB (Barry et al, 1992 and Brickman et al,
1993). Chlamydial EBs are unusual in that little or no peptidoglycan is present in the cell
wall. Structural rigidity is thought instead to be due to the highly cross-linked nature of
the outer-membrane complex. Inter and intramolecular cystine bonds exist between the
cysteine rich proteins of the outer envelope including OmpA, OmcB, and OmcA
(reviewed in Hatch, 1999).
Recent studies indicate the interaction of EBs with host cells occurs in a two-stage
process. The initial reversible attachment occurs through electrostatic interactions of the
bacteria with heparan sulfate containing glycosaminoglycans (Su et al, 1996; Su and
Caldwell, 1998; Stephens et al, 2001) and (Taraktchoglou et al, 2001); and a second,
irreversible, binding stage (Carabeo and Hackstadt, 2001). Clifton et al, 2004 have
recently shown that, immediately following the irreversible binding step, a type III
secretion system secretion system (TTSS) exported protein is delivered into the host cell.
This protein, termed Tarp (Translocated actin-recruiting phosphoprotein, CT456), is
rapidly phosphorylated at tyrosine residues and phosphorylation correlates spatially and
temporally with actin recruitment (Figure 1-1).
1.2.2

PRIMARY DIFFERENTIATION

The chlamydial developmental cycle has a singular enigmatic stage, the
differentiation of the infecting EB to a metabolically active RB. The process of
differentiation can be blocked by the addition of antibiotic inhibitors of transcription or
translation, suggesting that de novo protein expression is required to begin intracellular
growth (Scidmore et al, 1996). This finding is at odds with the generally held
understanding that the presence of the bacterial histone-like proteins HctA and HctB
render the EB transcriptionally incompetent. This paradox has been at least partially
addressed by the findings of Grieshaber et al, 2004 chlamydial histone–DNA interactions
are disrupted upon germination by a small metabolite in the non-mevalonate pathway
(MEP) pathway of isoprenoid biosynthesis. The metabolite is thought to be 2-Cmethylerythritol 2, 4-cyclodiphosphate and is involved in functional antagonism of HctA.
Findings showed that an E. coli HctA expression system was rescued from the lethal
effects of HctA by chlamydial ispE. ispE is an intermediate enzyme in the MEP
pathway, paradoxically; experimental data showed that E. coli orthologue of ispE could
not protect E. coli from the lethal effects of HctA expression.

2

Figure 1-1 A schematic representation of the chlamydial developmental cycle. The host
cell cytoplasmic membrane (red line) is shown to depict the interactions of chlamydial
EBs and the origin of the inclusion membrane. The major events in the developmental
cycle are categorized as described in the text to allow an overview of the processes and
mechanisms associated with acute and persistent chlamydial growth. TARP
(Translocated Actin-Recruiting Phosphoprotein, CT456), TTSS (Type III Secretion
System), MEP (non-Mevalonate Pathway), CPAF (Chlamydial Protease/proteasome-like
Activity Factor).
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The question arises whether it is special enzyme kinetics attributed to chlamydial
IspE or the transcriptional activity of the chlamydial ispE in the presence of HctA, or
another unknown function that chlamydial ispE has that helps in the rescue from HctA
lethality. Chlamydia possess another histone-like protein HctB, it is still unknown what
antagonizes its function during the differentiation step (Grieshaber et al, 2004).
Transcription begins within the differentiating RB almost immediately following
internalization. New protein expression can be detected within 15 min PI using intrinsic
labeling procedures (Plaunt and Hatch, 1988) and newly synthesized RNA can be
detected in “host-free” Chlamydia by 1 h PI (Crenshaw et al, 1990). Wichlan and Hatch
(Wichlan and Hatch, 1993) identified the first early gene (euo, Early Upstream open
reading frames [ORF]) using “host-free” early RNA to select clones from a genomic
library. Transcription of euo was confirmed by Northern blotting and primer extension
analysis. Euo appears to be specific to Chlamydia in that it is highly conserved within
the genus but has no homology to other bacterial proteins. Despite its early
identification, the function of Euo has not been clearly defined to date.
Following the sequencing of the serovar D genome, a number of studies used RTPCR to identify genes expressed early in the cycle. Shaw et al, 2000, identified a number
of inclusion-associated protein genes (inc) as early genes and proposed the generally
accepted temporal classes of developmentally expressed genes as (i) early (1–2 h PI), (ii)
mid-cycle (3–18 h PI), (iii) late (20–48 h PI). More recently, genome-wide DNA
microarrays have been used to determine the transcriptome throughout the cycle. Belland
et al, 2003b identified 29 genes expressed by C. trachomatis serovar D at 1 h PI in HeLa
229 cells. Seven of these genes had been previously characterized as early genes,
including the previously mentioned euo and inc genes.
1.2.3

RETICULATE BODY

The “reticulate body” (RB) arises from the internalized EB following primary
differentiation, as discussed above. RBs are larger than EBs (ca. 1 μm) and the
cytoplasm appears granular with diffuse, fibrillar nucleic acids, in contrast with the
highly condensed nucleic acid content of the EB (reviewed in Matsumoto, 2000). RBs
are non-infectious and are bounded by an inner and outer-membrane, resembling other,
Gram-negative, eubacteria. RBs undergo binary fission throughout the middle part of the
developmental cycle.
1.2.4

GENE EXPRESSION

Microarray analyses of gene transcription during the developmental cycle have
been reported for C. trachomatis serovar L2 (Nicholson et al, 2003) and serovar D
(Belland et al, 2003b). While a number of technical and experimental design differences
were used for the analyses, both reports indicate that by 6–8 h PI the developing RBs
were highly transcriptionally active. Belland et al (2003b) classified temporal gene
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expression groups into early, mid-cycle and late categories with a subgrouping of genes
expressed at 1 h PI as immediate-early. While this study focused on the immediate-early
and late genes, the complete listing of transcriptional activities (Belland et al, 2003b)
throughout the cycle indicated that the period of intense transcriptional activity (16–24 h
PI) correlated with the rapid growth and division of RBs. Furthermore, they reported that
virtually every gene in the organism is expressed at some point in the cycle, indicating
that C. trachomatis has virtually no facultative capacity, as might be expected for an
obligate intracellular organism with a “minimal” genome.
1.2.5

TYPE III SECRETION MACHINERY

Genomic data reveals that all chlamydial species possess a complement of genes
encoding TTSS (Stephens et al, 1998; Kalman et al, 1999) and (Read et al, 2000). TTSS
genes in Chlamydia show temporal regulation through out the developmental cycle
(Fields and Hackstadt, 2000; Fields et al, 2003; Slepenkin et al, 2003).
1.2.6

CELL DIVISION

Cell division takes place during the RB stage. Genome sequencing indicated that
Chlamydia lack an identifiable ftsZ orthologue, which encodes a protein centrally
involved in bacterial cell division and found in all other sequenced eubacteria. Another
surprising finding in the genomic analyses was the presence of a complete set of genes
for the synthesis, assembly, and degradation of peptidoglycan (PG) (Chopra et al, 1998;
Stephens et al, 1998; Read et al, 2000;) and (Read et al, 2003) Numerous studies had
reported that Chlamydia lacked peptidoglycan, with a single study reporting trace
amounts in EBs (Su H., 1985). Similarly, attempts to identify peptidoglycan in RBs were
unsuccessful (Barbour et al, 1982). Somewhat surprisingly, the production of infectious
EBs is highly sensitive to inhibitors of PG synthesis, including β-lactam antibiotics and
D-cycloserine (Matsumoto and Manire, 1970; Tamura and Manire, 1968; Weiss, 1950).
Treatment of infected cells with these agents inhibits cell division and leads to the
formation of large, aberrant RB that cannot differentiate to EB (Moulder, 1993). These
studies indicate that chlamydial PG synthesis may be required for chlamydial cell
division and proper differentiation. This paradoxical situation has been referred to as the
“chlamydial anomaly” (Ghuysen and Goffin, 1999). McCoy et al, 2003 have shown that
the chlamydial MurA orthologue (UDP-N-acetylglucosamine enopyruvyl transferase),
which catalyzes the first committed step in peptidoglycan biosynthesis, is functional in E.
coli. The chlamydial MurA was found to encode a fosfomycin-resistant form of the
enzyme and this resistance was imparted to E. coli expressing the chlamydial enzyme.
Expression studies indicated that Chlamydia are naturally fosfomycin resistant and that
murA is expressed at the point in the developmental cycle immediately preceding cell
division (Belland et al, 2003b) and (McCoy et al, 2003), providing circumstantial
evidence for the involvement of peptidoglycan synthesis in cell division. Brown and
Rockey (Brown and Rockey, 2000) have identified an antigen named the septum antigen
(SEP antigen) localized to a ring-like structure at the apparent septum within dividing
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chlamydial reticulate bodies (RB). Antisera directed against SEP show similar patterns
of antigen distribution in C. trachomatis and C. psittaci RB. Treatment of chlamydiae
with inhibitors of peptidoglycan synthesis or culture of chlamydiae in medium lacking
tryptophan leads to the formation of nondividing, aberrant RB. Staining of aberrant RB
with anti-SEP reveals a marked redistribution of the antigen. The reversal of aberrant
formation results in the production of normal RB and a redistribution of SEP to the
apparent plane of bacterial division.
1.2.7

SECONDARY DIFFERENTIATION AND LATE GENE EXPRESSION

Following the period of rapid cell division, RBs begin to redifferentiate to EBs,
here termed “secondary differentiation”. The signal for this process is unknown and
efforts to identify quorum sensing type pathways are not been supported by genomic
analyses.
Expression of a number of late-cycle genes occurs during secondary
differentiation (reviewed in Hatch, 1999), including genes that encode components of the
outer-membrane complex (e.g., OmcA and B) and proteins involved in the condensation
of the chromosome (e.g., HctA and B). Microarray analyses have extended the number
of genes expressed during this stage of development. Belland et al, 2003b identified 26
late genes including a number of genes previously characterized as late genes based on
other molecular biological studies (e.g., omcAB, hctAB, ltuB, lcrH.1) and a number of
new genes that encode proteins with speculative and unknown function. Interestingly,
expression of some late cycle genes may be directed towards the arming of EBs with
proteins necessary during the early stages of the next infectious cycle (e.g., the TTSS
protein LcrH.1), hence “late” genes may encode “early” proteins.
1.3
1.3.1

PROMOTER ELEMENTS AND REGULATION

PROMOTER ELEMENTS IN E. coli.

The bacterial core RNA polymerase complex, consists of five subunits (ββ’α2ω),
these subunits are sufficient for transcription elongation and termination but are not able
to initiate transcription. Transcription initiation from prokaryotic promoter requires
another dissociable subunit (σ70 factor) (Burgess et al, 1969), which reversibly associates
with the core RNA polymerase complex to form a holoenzyme RNAP. (reviewed in
Paget and Helmann, 2003).
An RNAP-promoter complex capable of transcription initiation is formed through
interactions that involve several regions of RNAP and that span 70–80 base pairs (bp) of
promoter DNA (~−60 to +20) with respect to the transcription start site (TSS). The
majority of the sequence-specific interactions occur with the σ subunit. In E. coli,
sequence-specific interactions with σ70 occur at the −10 element (regions 2.3–2.4 in σ70),
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the extended −10 element (σ70 region 3.0), the −35 element (σ70 region 4.2), and the
discriminator element immediately downstream of the −10 hexamer (σ 70 region 1.2),
Figure 1-2; and (Haugen et al, 2008). In addition, the C-terminal domain of α subunit
can interact sequence-specifically with the UP element, located upstream of the −35
hexamer (Gourse et al, 2000). Other interactions also take place that are not sequence
specific (Korzheva and Mustaev, 2001; Murakami et al, 2002; Vassylyev et al, 2007).
(Reviewed in Ross and Gourse 2009).
1.3.2

CHLAMYDIAL GENE REGULATION

Control of the developmental cycle may have important translational and posttranslational components but the bulk of the experimental evidence suggests the primary
mechanism involved is transcriptional regulation. Genomic studies have shown that all
species sequenced to date (Stephens et al, 1998; Read et al, 2000; Read et al, 2003) have
a highly conserved multisubunit RNA polymerase that has many shared features
compared to other eubacterial RNA polymerases (i.e. the core RNA polymerase consists
of two α subunits and β and β’ subunits). Three sigma factors (σ) that combine with the
core polymerase to form the holoenzyme have also been found in all sequenced species.
The chlamydial-specific sigma factors are the major sigma factor σ66 (Koehler et al,
1990; Mathews and Stephens, 1999a; Douglas and Hatch, 2000) (orthologous to σ70 in E.
coli) and the minor sigma factor σ28 (Mathews et al, 1999b; Yu and Tan, 2003; Shen et
al, 2006) (orthologous to σ28 in E. coli) and the alternative sigma factor σ54 (Mathews and
Timms, 2000) (orthologous to σ54 in E. coli). Functional evidence has been demonstrated
for several σ66 promoters and one σ28 promoter using mutational analysis and in vitro
transcription assays (e.g. Ricci et al, 1993; Fahr et al, 1995; Douglas and Hatch, 1996;
Tan et al, 1996; Tan et al, 1998; Ochiai et al, 1999; Schaumburg and Tan, 2003; Yu et al,
2003; Yu et al, 2006). Chlamydial promoters share homology with each of the
eubacterial consensus sequences with certain exceptions, including the presence of a cisacting, A/T spacer region in the majority of σ66 promoters analyzed (Schaumburg and
Tan, 2000). In addition, the stringency of consensus in chlamydial promoters appears to

Figure 1-2 Consensus sequences for Eσ70 recognition elements and RNAP regions that
interact with these elements. UP Element with α subunit C-terminal domains, −35
hexamer with σ70 4.2, extended −10 element with σ70 3.0, −10 hexamer with σ70 2.3–2.4,
and discriminator region element with σ70 1.2. The TSS is indicated as (+1). The most
common spacing between recognition elements, in bp, with (range) is indicated. Both the
spacing of the −35 element with respect to the extended −10 element (14bp), and with
respect to the −10 element (17bp) are shown. Reprint by permission: Ross W, Gourse RL
(2009) Analysis of RNA polymerase-promoter complex formation. Methods 47: 13-24.
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be more relaxed than found in other eubacteria (Mathews and Sriprakash, 1994), allowing
for changes in the consensus -10 and -35 regions of the promoters that interact with the
major sigma factor. This lack of stringency has hampered in silico efforts to identify
promoters from complete genome sequences.
Several transcriptional regulatory mechanisms have been found in Chlamydia
including cis-acting DNA elements (Schaumburg et al, 2000), phosphorylation cascades
(Koo and Stephens, 2003) and transcription factors (activators and repressors).
Transcriptional regulators have been found that repress transcription. HrcA has been
shown to specifically bind a chlamydial CIRCE (Controlling Inverted Repeat for
Chaperone Expression) element upstream of dnaK (Wilson and Tan, 2002), and a
degenerate CIRCE element upstream of groELS (Wilson et al, 2005) and repress
transcription of the dnaK and groELS genes.
A distant relative of the E. coli fur gene has been identified in Chlamydia (termed
dcrA) by complementation of an E. coli fur mutant and the ability to bind a 19 bp
consensus operator sequence (or Fur box) found in promoters of iron-regulated genes
(Wyllie and Raulston, 2001). The repressor-operator binding kinetics of DcrA differ
from the E. coli Fur protein suggesting that DcrA may have additional response cues than
its E. coli counterpart or that the chlamydial operator sequence may differ from the
consensus Fur box. Other regulators include IHF (Zhong et al, 2001), TrpR (Akers and
Tan, 2006), ArgR (Schaumburg and Tan, 2006) and ChxR (Koo et al, 2006).
1.4

ALTERNATIVE GROWTH MODELS AND PERSISTENCE

Many chlamydial diseases are associated with a long term or chronic infectious
state. In most cases it is difficult to establish whether chronic or recurrent infections arise
through the inability of the host to resolve the infection or the occurrence of repeated
infections with similar species or genotypes. Despite the unresolved nature of the disease
etiology, persistence models of chlamydial infection have been studied to provide insight
into the nature of chronic disease (reviewed in Hogan et al, 2004). Persistence is defined
as a long-term association between Chlamydia and their host cell in which these
organisms remain in a viable but culture-negative state. The in vitro persistence systems
often share altered chlamydial growth characteristics for example, many studies have
described enlarged, and pleomorphic RBs that neither undergo binary fission, nor
differentiate to EBs, but nevertheless continue to replicate their chromosomes. These
changes are generally reversible upon removal of the growth inhibitory factor (Hogan et
al, 2004). Persistent in vitro infections have been induced by penicillin treatment
(Matsumoto et al, 1970), amino acid starvation (Coles et al, 1993), iron deficiency
(Raulston, 1997), IFN-γ exposure (Beatty et al, 1993), monocyte infection (Koehler et al,
1997), phage infection (Hsia et al, 2000), continuous culture (Kutlin et al, 2001). This
subject has been thoroughly reviewed in Hogan et al, 2004.
IFN-γ mediated inhibition of intracellular chlamydial replication occurs by
depletion of the essential amino acid tryptophan, via the induction of indoleamine-2,3-
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dioxygenase (IDO) (Beatty et al, 1994). The effect of IFN-γ on chlamydial infection
could be reversed by addition of tryptophan (Byrne et al, 1986). Belland et al. have
studied the induction of persistence with IFN-γ and the subsequent reactivation, using
microarray analysis. Persistent growth, characterized by large aberrant RBs, led to the
up-regulation of genes involved in tryptophan utilization, DNA repair and recombination,
phospholipid biosynthesis and translation. Up-regulation of the repressible trp BA
operon (Wood et al, 2003) confirms the previous observations that IFN-γ treatment
reduces intracellular concentrations of tryptophan. In addition, a number of early genes
were up-regulated, particularly the euo gene (30-fold increase) which encodes a DNAbinding protein that has been shown to bind to a late gene promoter region (i.e. omcAB
(Zhang et al, 1998). Down-regulation of genes involved in RB to EB differentiation (late
genes such as hctAB and omcAB), proteolysis and peptide transport, and cell division
were seen during persistent growth. The transcriptional analyses were consistent with the
biological properties associated with aberrant RBs in that cells were blocked in
cytokinesis and the developmental cycle was arrested at a point preceding late gene
expression. Removal of IFN-γ and supplementation with added tryptophan led to a rapid
reactivation from persistent growth. During reactivation the expression differences
rapidly returned to control levels, i.e. euo expression dropped 20-fold in 12 h. This
coordinated biological response appears to have evolved to allow the organism to rapidly
respond to immunological pressure in a manner that allows for a period of resistance
followed by rapid recovery after the waning of the host response.
1.5
1.5.1

REGULATORY ncRNAs IN BACTERIAL PATHOGENS

GENERAL

Bacterial RNAs have long been known to encode the information for protein
expression (mRNAs) and the structural components of the translational machinery
(tRNAs and rRNAs). Numerous studies have proved that there are other type(s) of RNAs
with other functions. For example, a number of abundant and frequently stable RNAs
were identified by metabolic labeling and direct analysis by various fractionation
procedures. These included: 1) 4.5S RNA, part of the secretion machinery (Ribes et al,
1990); 2) the catalytic part of the RNase P Ribozyme (M1RNA) (Robertson et al, 1972),
that was found to be a ubiquitous endonuclease catalyzing the maturation of the 5' end of
tRNA (reviewed in Kazantsev and Pace, 2006); 3) tmRNA, which serves an important
role in translational quality control (Komine et al, 1994); 4) 6S RNA, which modulates
RNA polymerase activity (Narayan et al, 1966; Barrick et al, 2005); and 5) Spot 42, an
ncRNA that acts as an anti-sense regulator of the gal operon (Ikemura and Dahlberg,
1973; Moller et al, 2002). Not surprisingly, this sort of regulation is not confined to E.
coli. Phages, plasmids and transposons have long been recognized to use anti-sense RNA
regulators involved in controlling copy number of plasmids, transposons, and the life
cycle of bacteriophages (reviewed in Delihas, 1995; Wagner and Brantl, 1998; Wagner et
al, 2002). In eukaryotic cells, microRNAs and RNAi parallel in many ways bacterial
ncRNA regulators; confirming that this level of regulation is widespread and is as central
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to creating a working organism as are the more highly characterized protein regulators of
transcription (Carrington and Ambros, 2003; McManus and Sharp, 2003).
1.5.2

FUNCTIONAL ASPECTS

Since the discovery of this new category of ncRNAs, several exhaustive searches
have taken place. This lead to the identification of approximately 80 ncRNAs in E. coli
between 50 and 400 bases in size (1%–2% of the number of protein-coding genes)
(Argaman et al, 2001; Gottesman et al, 2001; Rivas and Eddy, 2001; Wassarman et al,
2001; Kawano et al, 2005). Mechanistically, ncRNAs act through base-pairing
interactions with other RNAs, thus inducing premature termination of message (Novick
et al, 1989), mediating the destabilization of target mRNAs (Masse et al, 2003; Morita et
al, 2005), promoting efficient translation of target mRNA (Majdalani et al, 1998),
negatively regulating translation of target mRNA (Grieshaber et al, 2006) by mimicking
the structure of other RNAs and DNAs (Willkomm and Hartmann, 2005), or as integral
parts of protein-RNA complexes (Ribes et al, 1990) (reviewed in Storz et al, 2004;
Gottesman, 2005 and Waters and Storz, 2009).
Regulatory ncRNAs can be broadly divided into cis and trans-acting molecules.
Cis-acting ncRNAs (also termed anti-sense RNAs) generally overlap the target gene and
form extensive complementary stretches of double stranded RNA (dsRNA) that are
degraded by RNase III (Vogel et al, 2004), or cause premature termination (attenuation)
of transcription (Novick et al, 1989). Trans-acting ncRNAs interact with nonoverlapping target mRNAs and the resulting RNA hybrids are generally degraded by
RNase E (Masse et al, 2003), or the binding interaction interferes with recognition of the
translational start portion of the mRNA (reviewed in Storz et al, 2004), or act as anti-antisense where they remodel target RNA in favor of a translational permissive secondary
structure (Majdalani et al, 1998). Trans-acting ncRNA function is often difficult to
predict since the anti-sense interaction generally occurs through a limited number of base
pairs with the target mRNA, often using non-contiguous regions of the molecule folded
into hairpin loops. Many trans-acting ncRNAs have been shown to bind multiple target
sequences; e.g. RyhB that binds to the mRNA of several iron metabolizing genes and
possibly other targets as well (Masse et al, 2005).
1.5.3

DETECTION METHODS

Identification of bacterial ncRNAs has increased dramatically with the advances
in genomic technology and the appreciation of the importance of these molecules in
regulatory pathways. Experimental approaches to identifying ncRNAs (reviewed in
Huttenhofer and Vogel, 2006; Vogel and Sharma, 2005) have been diverse and include: i)
direct metabolic labeling of abundant ncRNAs and detection by gel electrophoresis, ii)
genetic screens for regulatory phenotypes that mapped to non-coding regions, iii) cloning
of size fractionated RNAs, iv) bioinformatic identification of conserved intergenic
regions, v) co-purification with RNA-binding proteins, and vi) microarray analysis of
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intergenic regions. Although each approach has strengths and weaknesses, a microarray
analysis has become the method of choice for initial identification. Traditionally,
microarray design has been limited to regions coding for proteins, thereby omitting
transcriptional measurements in intergenic regions (IGRs) where the majority of ncRNAs
are encoded. Recent studies with E. coli have utilized high-density microarrays that
contain overlapping 25’mers oligonucleotide probes for all mRNAs, tRNAs, and rRNAs
and IGRs (Selinger et al, 2000). Although initially used to validate technical aspects of
microarray profiling, a number of ncRNAs were confirmed using this procedure.
Subsequent studies, specifically directed at ncRNA detection, have shown the approach
to be particularly useful in analyzing ncRNA expression under different growth
conditions (Wassarman et al, 2001; Tjaden et al, 2002). An alternative approach has
been used to analyze intergenic expression patterns in Staphylococcus aureus that
involved PCR amplification of selected regions and arraying the dsDNAs on glass slides
(Pichon and Felden, 2005).
1.5.4

KNOWN EXAMPLES OF ncRNAs

Recent studies have shown that, in addition to the plethora of protein repressors
and activators, ncRNAs act as major regulators of adaptive responses in bacterial
pathogens. These ncRNAs control the global response of E. coli to oxidative stress
(Altuvia et al, 1997), iron starvation (Masse et al, 2005), glucose starvation (Vanderpool
and Gottesman, 2004), and the expression of outer membrane proteins and porins
(Rasmussen et al, 2005; Udekwu et al, 2005). Several pathogens utilize a cell-density
based system (quorum sensing) to control the expression and secretion of virulence
factors. Non-coding RNAs were found to be the main effectors of quorum sensing
systems in some organisms, e.g. in Vibrio cholerae, the expression of four redundant Qrr
RNAs (quorum regulatory RNAs) is dependent on the quorum sensing protein
(phosphorylated LuxO at low cell density) to block expression of the downstream
effector, HapR (Lenz et al, 2004). This leads to the up-regulation of a large number of
virulence factors. In Staphylococcus aureus, the expression of virulence factors is
controlled by the expression of RNAIII that acts as the intracellular effector of the agr
regulon (Novick and Jiang, 2003). In Streptococcus pyogenes, the pel locus encodes a
pathogenesis-related RNA that forms part of a signal transduction cascade that is
dependent on the growth phase of the organism (Mangold et al, 2004). The multifaceted
effects of ncRNAs can be illustrated by the S. aureus RNAIII (Novick et al, 2003)
molecule, which controls the switch between the expression of surface proteins
(colonization) and secreted toxins (pathogenicity). The RNAIII molecule uses different
structural domains to act in three different ways: 1) as a translational activator for hla
(hemolysin δ) (Morfeldt et al, 1995); 2) as a translational inhibitor of spa mRNA; and 3)
as a hemolysin mRNA (Novick et al, 2003). RNAIII is also thought to regulate the
expression of approximately 110 other genes, but it is not known if this is a direct effect
on transcription or the result of post-transcriptional regulation of other transcription
factors (Dunman et al, 2001). Recently, Grieshaber et al, 2006 have shown that
heterologous expression of a ncRNA from C. trachomatis can block translation of HctA
(a chlamydial histone) in E. coli, thereby rescuing chlamydiae from the lethal effects of
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HctA expression. In addition, they demonstrated that the ncRNA (ihtA) was
developmentally expressed in C. trachomatis at times in the cycle when HctA was not
expressed.
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CHAPTER 2. MATERIALS AND METHODS
2.1

MICROARRAY DESIGN AND CONSTRUCTION

The custom microarray was designed in conjunction with the Affymetrix Design
Team and purchased through support of the University of Tennessee Health Sciences
Center and the UT Center of Excellence for Genomics and Bioinformatics. The custom
microarray is termed the “Multi-Pathogen Array, University of Tennessee number 1” or
MPAUT-1, as it has representations of four chlamydial genomes of four different species.
The species represented are C. trachomatis D (Stephens et al, 1998), C. pneumoniae AR39 (Read et al, 2000), C. muridarum (Read et al, 2000), and C. caviae (Read et al, 2003)
and the complete genomic sequences are available on the TIGR website (www.tigr.org).
The custom array format is a “CustomExpress Advantage 49-7875” that has
approximately 253,000 addressable features (i.e. defined positions for 25’mer
oligonucleotides termed “probes”). Sequences of the complete ORFs for each species
were submitted to the Affymetrix Design Team as FASTA files and probes were selected
based on their evaluation process. This process looks at all possible 25’mer probes and
assigns probe scores based on a number of criteria including; thermodynamic properties,
hybridization potential, synthesis steps, and cross-reactivity. Cross-reactivity was
addressed by a series of steps involving “hard” pruning (elimination of probes that crossreact with abundant RNAs, i.e. rRNAs) and “soft” pruning (elimination of probes that
cross-react with other sequences on the microarray and internal control sequences). Each
ORF is represented by a number of 25’mer oligonucleotides (mean value, 11 25’mers per
gene) that are species-specific. Each probe (termed Perfect Match or PM) has a
corresponding mismatched probe (MM, altered at position 13, the middle of the 25’mer)
to control for specificity. The values reported for ORF analysis are therefore the mean
value of the 11 measurements i.e. ∑ 𝑃𝑃𝑃𝑃 − 𝑀𝑀𝑀𝑀⁄11.
2.2

C. trachomatis GROWTH AND CELL CULTURE

C. trachomatis serovar D (strain UW-3/Cx) was grown in HeLa 229 cells
cultivated at 370 C with 5% CO2 in high glucose-containing DMEM (Cellgro, Mediatech)
supplemented with 10% heat-inactivated FBS. EBs were purified on density gradients of
RenoCal-76 (Bracco Diagnostics, NJ) as previously described (Belland et al, 2003b).
Monolayers were pre-treated with DEAE-Dextran (30 µg/ml) and infected at a
multiplicity of infection (MOI) of 1. PI timing began immediately following the addition
of infectious EBs to the monolayers. Growth in the presence of IFN-γ was done as
described previously (Belland et al, 2003a). 5ng per ml IFNγ was used to induce
persistence. The amount of IFN-γ used was determined based on a titration experiment
for the minimum amount of IFN-γ that induce persistence and allowed for reactivation.
Carbenicillin-persistence was induced by adding 2 µg per ml antibiotic to the media at
the time of infection. Similar to the IFN-γ experiments, the amount of carbenicillin used
was determined by a titration experiment that allowed for reactivation.
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2.3

RNA PURIFICATION

Total RNA was purified from infected HeLa 229 cultures (9 x 105 cells per well
cultivated as monolayers in 6 well culture plates) at various times PI. At the designated
times PI, the culture media was discarded and cells lysed in 1 ml per well lysis buffer
containing Proteinase K (0.167 µg/µl) (MasterPureTM, Epicentre) and total nucleic acid
was isolated. An aliquot of the lysate (300µl) was treated with RNase A (0.0167 µg/µl)
and used to purify DNA. The remainder of the lysate was treated with DNase I and used
for total RNA preparation according to manufacturer’s instructions (MasterPure,
Epicentre). Purified DNA was quantified by qPCR and used for RNA normalization to
calculated C. trachomatis genome numbers as previously described (Ouellette et al,
2006). RNA for microarray analysis was further purified from residual contaminating
DNA by treating with DNase I (0.3U per 1 µg RNA) at 37oC for 1 hour (TurboDNAFree,
Ambion). RNA was then precipitated using sodium acetate (0.1 volume) and ethanol (3
volumes) overnight at -20oC. RNA was then pelleted by centrifugation, washed with
80% ethanol and re-suspended in DPEC water (1µg/µl). RNA (250 µg) was then
enriched using the MICROBEnrichTM (Ambion) and MICROBExpressTM (Ambion)
protocols, resulting in the removal of a significant portion of HeLa cell polyadenylated
mRNA, 18S and 28S rRNAs in addition to bacterial 16S and 23S rRNA.
RNA was reverse transcribed, hybridized, washed, stained, and scanned according
to the Prokaryotic sample and array processing section in the GeneChip Expression
Analysis Technical Manual (Affymetrix, CA). In short, cDNA was generated from
enriched RNA preparations using random primers (Invitrogen, CA) and Superscript RT II
(Invitrogen, CA). Following cDNA generation, RNA was removed by adding NaOH (1
N) and incubating for 30 min at 65°C followed by neutralization in HCl (1 N). cDNA
was then purified using MinElute columns (Qiagen, CA). cDNA was then fragmented
using DNase I (Amersham, UK) using 0.6 U per 1μg of cDNA generated. Fragmented
cDNA products were then end-labeled using GeneChip DNA labeling Reagent
(Affymetrix, CA) and Terminal Deoxynuceotidyl Transferase (Promega, WI).
Fragmented and labeled cDNA were analyzed using 4-20% TBE gels (Invitrogen, CA)
using a gel shift assay using NeutrAvidin (NeutrAvidin, Pierce). The hybridization
cocktail, consisting of labeled cDNA, control B2 oligo (Affymetrix, CA), herring sperm
DNA (Promega, WI), and BSA (Invitrogen, CA) was then hybridized to MPAUT-1
GeneChip and incubated for ca. 16 h in the Affymetrix Hybridization Oven 640
(Affymetrix, CA) at 45°C rotating at 60 rpm. Samples were then washed and stained on
the Affymetrix Fluidics Station 450 (Affymetrix, CA) using Streptavidin (Pierce, IL),
Anti-Streptavidin antibody (Vector Laboratories, CA), and R-Streptavidin Phycoerythrin
(Molecular Probes, CA) and using fluidics protocol ProKGE-WS2_450 in GCOS 1.1
(Affymetrix, CA). After washing and staining, completed chips were scanned using the
Genechip Scanner 3000 (Affymetrix, CA). Data was scaled using GCOS 1.1
(Affymetrix, CA) to a mean intensity of 1000 using the C. trachomatis ORF's as a scaling
mask. The pivot file for the sample was then saved in GCOS as a text tab delimited file
and the data was imported into GeneSpring 7.2 (Agilent, CA) for data analysis.

14

2.4

QUANTITATIVE RT-PCR

Primer/probe sets have been designed for C. trachomatis ompA using Primer
Express software (Applied Biosystems, CA). Standard curves were performed using
purified chromosomal template DNA at concentrations ranging from 10 - 0.001 ng/ml
(data not shown). Assays were performed (Universal PCR System, Applied Biosystems)
using DNA preparations of a portion of the sample for RNA purifications that were used
for Northern Blotting. Bacterial genome copy numbers were estimated by converting
mean critical threshold (Ct) values to DNA concentrations (using Standard curves) and
converting concentrations to copy numbers using the calculated molecular mass of the
bacterial genome (7700 Sequence Detector, ABI Prism).
2.5

RNA CIRCULARIZATION, AND 5’/3’ END SEQUENCING

The procedure for RNA 5’/3’ end sequencing has been described previously
(Vogel and Hess, 2001) and was used with some modifications. A total of 8 µg of DNAfree total RNA (DNased twice) prepared from 24 h PI cultures was treated with ten units
tobacco acid pyrophosphatase (Epicentre, WI) for 30 min at 37°C to convert 5’
triphosphate groups of primary transcripts to 5’ monophosphates. Following organic
extraction, RNA was treated with 40 U of T4 RNA ligase (New England Biolabs, MA)
overnight at 17°C. RNA concentration during ligation was kept at 0.5 µg/50µl; this
dilution allowed the reaction to proceed in the direction of intramolecular ligation
(circularization) rather than intermolecular ligation (concatemerization). Following
organic extraction and ethanol precipitation, 1.5 µg of self-ligated RNA was converted to
cDNA using gene specific reverse primes (Table 2-1) under 5’3’ SEQ application
heading) and Superscript III (200 units) reverse transcription kit (Invitrogen, CA) in a 20
µl reaction. Incubation was carried out in 20-minute intervals at 42 °C, 50 °C, 55 °C, and
60 °C. After heat inactivation of the reverse transcriptase for 5 min at 85 °C, cDNA was
treated with one unit of RNase H (New England Biolabs, MA) at 37 °C for 20 min. A
total of 1 µl of the reaction served as template in a subsequent standard 25 µl PCR
reaction using TITANIUM Taq DNA Polymerase, TaqStart Antibody (1.1 μg/μl), 1x
Advantage 2 SA PCR Buffer (Tris-HCl 1 mM (pH 8.5), KCl 5 mM, MgCl2 0.2 mM), and
0.2 mM dNTP (Clontech, CA) and primer pairs designed to amplify products
representing successful self-ligated ncRNA transcripts. PCR products were separated by
10% PAGE TBE gel electrophoresis (BIORAD, CA), and fragments of the expected size
were excised, incubated overnight in 10mM Tris-HCl buffer then cloned into the pCR
2.1-TOPO vector (Invitrogen, CA). Positive colonies were picked, grown overnight in
LB media with carbenicillin (50 µg/ml) and plasmid were prepare using MiniPlasmid
Prep (Qiagen, CA). Plasmids were sequenced using a standard M13 Forward primer.
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Table 2-1 List of primers, organized according to application.
Application/
Primer Name
Use

Sequence
TAATACGACTCACTATAGGGAG
ATTCTCCGCGATGGCACCTTAA
T
TGTGATAGCCTGAGCGTGTAGA
TG
TAATACGACTCACTATAGGTAG
CTCTTGCAGAGAAGCATCGTG
CCGTCTCAAATGTCTACTGTCG
CT
AGGTTCCCTTGAAAGACACGGT
CA
CCGTCTCAAATGTCTACTGTCG
CTGC
AGGTTCCCTTGAAAGACACGGT
CA
ACTACCATCCGGGAATGATTAG
ACGCTTCCGT
CCTTTGGAGTATATTTGAGGCG
G
TAATACGACTCACTATAGGGGG
AGAACTCAGAGGG
CCCTCTGAGTTCTCCCCCGAA
GGGTGCTGGTCACTAGCAAAAA
CTAGA
GGGAGAACTCAGAGGG
GGGTGCTGGTCACTA
CTACGTCATCTGTCAGAGAAAG
AGC
TAATACGACTCACTATAGGAGG
AATGGAATCGCAAATAGTGAG
ACACGCCTAGGGCTATCTCTTG
TT
TAATACGACTCACTATAGGTCC
CTACAGGAGGTTTAGAGGCTT

CTIG153_FWD_T7
CTIG153
Northern

CTIG153_REV
CTIG153band2_FWD_T7
CTIG153band2_REV

CTIG153
5’3’ SEQ

CTIG153
5’RACE

CTIG241
Northern
CTIG241
5’3’ SEQ
CTIG241
5’RACE
CTIG270
Northern

CT270
Northern

CTIG153 FWD 5'3' SEQ
CTIG153 REV 5'3'SEQ
CTIG153_GSP1
CTIG153_GSP2
CTIG241_FWD
CTIG241_REV_T7
CTIG241 FWD 5'3'SEQ
CTIG241 REV 5'3'SEQ
CTIG241_GSP1
CTIG241_GSP2
CTIG270_FWD
CTIG270_REV_T7
CT270_FWD
CT270_REV_T7
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Table 2-1 continued.
Application/
Primer Name
Use
CTIG270
Probe -219
to -18

CTIG270
Probe -106
to +67

CTIG270 REVT7(-18)
CTIG270_FWD(-106)
CTIG270_REVT7(+67)
CTIG270_FWD(+83)

CTIG270
Probe
+275 to
+494

CTIG270_FWD(+275)

CTIG270
5’RACE

TTTAGCCGGAATATTCTGAAGA
AGTTGGTCTAAATG
TAATACGACTCACTATAGGAGA
GTTACTTTTTTTGTGAAAGAGT
AAAAAGACGAGTTC
GTCAAGCTTTGTCGACTAACTA
CGTCATCTG
TAATACGACTCACTATAGGAGC
GGGAGAGGAAACTAATAATAA
AGA
CTGCACACTCATCCCAAAGCAA
CA
TAATACGACTCACTATAGGGAG
AATAGCTTCTCGAGTGCTGCCT
AGCACACCGTCCTCCCATATAG

CTIG270 FWD(-219)

CTIG270
Probe +83
to +264

CTIG270
5’3’ SEQ

Sequence

CTIG270 _REVT7(+264)

TAATACGACTCACTATAGGACT
AAGGGATATTCTAGTGCAGGG

CTIG270_REVT7(+494)

CACTCATCCCAAAGCAACAGAC
CTCA
AGTGTGCAGCCTGGCATAAGGA
AA
GAGGAATGGAATCGCAAATAG
TGAG
TTGGGATGAGTGTGCAGCCTGG
CATAA
AATCACCGTAGACAATTAACTC
TGATCGTTGTTG
GGACGACGATGACAAAAATCA
CCGTAGACAATTAACTC
ATTGGCCGGCCATGGACTACAA
GGACGACGATGACAAAAATCA
ATTAGGCCTCTATTTGCGATTCC
ATTCCTCATATAGCAGCT
ATTAGGCCTGCCGATTCATTAA
TGCAGCTGG

CTIG270 FWD 5'3' SEQ
CTIG270 REV 5'3'SEQ
CTIG270_GSP1
CTIG270_GSP2
CT270_NoATG FWD
CT270 FWD+0.5FLAG

ftsI-FLAG
Cloning

CT270 FWD FseI/FLAG
CT270_REV+Stop/StuI
LacP/O/S.D.+StuI_FWD
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Table 2-1 continued.
Application/
Primer Name
Use
ftsI-FLAG
LacP/O/S.D.+FseI_REV
Cloning
CTIG270
Cloning

CTIG327
Northern

Sequence
AATCCGGCCGGTTTCCTGTGTG
AAATTGTTA
ATGAAAGCTTAGAAATGTTTTG
TTTGTGAGATGTAATTATGA
ATTAAAGCTTTACTAAGGGATA
TTCTAGTGCAGGG
TAATACGACTCACTATAGGACA
CCCGTCTCTAAGAAGTAGGCA
GTAACAAGGTGTTGTGTAATCA
GAACT
TTCTGGTCTACAGAGGGCTTT
TTAAGTACTGCTCGAACCCGTA
ACGC
CGGAGTCCTTCGAATTACACCA
GGATCT
GTCAAAGCAAGCCTTCTGGTCT
ACAGAG
CCTCTGTAGACCAGAAGGCTTG
CTTTGACT
TCGGTCTCTATCCTTAAGTACTG
CTCGAACCCGT
TAATACGACTCACTATAGGTAA
CAGCACGTTCCACTACTCGCA
GTTTATGTCTCAACTCAGCTAA
ACGC
GGACCCAGCCGTCAGAACACTT
T
AGCTGCTTTGTTTGGGTGTTTGC
C
TAATACGACTCACTATAGGTAA
GAACAAGGACCCGGCGATAAC
TCCTTTCATTTAGACTGGAGA
CCGGCCTTTAAACCAACTACAG
ACATCC
CCGGATACCTTAGTGTCGATTC
GGTGAA

CTIG270_FWD/HindIII
CTIG270_REV/HindIII
CTIG370_FWD_T7
CTIG370_REV_all gene
CTIG370_REV_PostTerm
CTIG370 FWD SEQ 3'5' RT

CTIG327
5’3’ SEQ

CTIG370 FWD 5'3' SEQ
CTIG370 REV SEQ3' 5'

CTIG327
5’RACE

CTIG356
Northern

CTIG356
5’3’ SEQ
CTIG360
Northern
CTIG360
5’3’ SEQ

CTIG370_GSP1
CTIG370_GSP2
CTIG356_FWD_T7
CTIG356_REV
CTIG356 FWD SEQ 3'5'
CTIG356 REV SEQ 3'5' RT
CTIG360_FWD_T7
CTIG360_REV
CTIG360 FWD SEQ 3'5'
CTIG360 REV SEQ 3'5'
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Table 2-1 continued.
Application/
Primer Name
Use
CTIG360
5’RACE

CTIG498
Northern

Sequence
CTGCTATCCCACACATAGGACT
AC
AGAACAAGGACCCGGCGATAA
CCTTCACAA
ACCTGGAACAGCAGAGTTGATT
GTGGCT
TAATACGACTCACTATAGGGGC
TTTCACCAGGCGATGGGAAGAA
G
CAGCATAATTTCGGAATCGAGC
G
CAGCATAATTTCGGAATCGAGC
GAAGTCT
GGCTGTGAGTTCCCTGGATAAA
CAAGT
TAATACGACTCACTATAGGACA
AGAAGTTCTAGCACGCACGAC
CCGAAGAATCTCAAGAGCAGCC
AA
CTTCTTGTAAAGCTGTGGCGAG
GACT
AGTTCTAGCACGCACGACTGGA
AA
GCAAATTCTTGCTTTAGCAGGC
AGG
TAATACGACTCACTATAGGTAA
GCGGGATCTTAGTCTCTCGCA
AAAGAGCTTATATGTGAAAGAC
TTTGTGT
GCTCTTTTGAGAGCTTTCTTGGA
AAGCTTGA
CTCAAAAGAGCTTATATGTGAA
AGACTTTGTGTCATA
AGCGCGCTTCTTCCGCTCTT
AGCCTTGTCAGGGACTTTAAAC
GGG

CT359_GSP1
CT359_GSP2
CTIG498 FWD
CTIG498 REV_T7
CTIG498 REV SEQ 3'5' RT

CTIG498
5’3’ SEQ

CTIG498 REV SEQ 3'5'
CTIG498 FWD SEQ 3'5'

CTIG504
Northern

CTIG504
5’3’ SEQ

CTIG643
Northern

CTIG504_FWD_T7
CTIG504_REV
CTIG504 REV SEQ3'5'
CTIG504 FWD SEQ3'5' RT
CTIG643_FWD
CTIG643_REV_T7
CTIG643 FWD RT

CTIG643
5’3’ SEQ

CTIG643 FWD SEQ 3'5'
CTIG643 REV SEQ 3'5'
CTIG643 FWD SEQ 3'5'-2
CTIG643 REV SEQ 3'5'-2
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Table 2-1 continued.
Application/
Primer Name
Use
CTIG675
Northern
CTIG675
5’3’ SEQ
CTIG675
5’RACE

CTIG675
Cloning

Sequence
TAATACGACTCACTATAGGTTG
CAAGTTGGTATTCTAACGCC
AAAGCCAAGAGAACCGGAGAT
ACG
CCGTATCTCCGGTTCTCTTGGCT
GGCTAACTCCAGTCCATCTTGA
CTTCC
TACGGCTAACTCCAGTCCATCT
TGACTTCC
CAAACACTAGAGTCAGAAGCTA
TTCCATGGCGTT
ATTTTCATTAAGCCGAAAGTCA
TCAGTAGCTTCGA
TACGAATGCGTTGCTCTACCAA
CTGA
GTGATAGAGATACTGAGCACAG
TTGCAAGTTGGTATTCTAACGC
C
AGAGATTGACATCCCTATCAGT
GATAGAGATACTGAGCAC
TCGAGTCCCTATCAGTGATAGA
GATTGACATCCCTATCAGTGAT
CGTAGGTACCTCGAGTCCCTAT
CAGTGATAGAGATTGACA
GCAATACTCTCTCTGACTGTCT
AGC
TAATACGACTCACTATAGGAGA
CAGCCTAGGGAAAGAGGATGT
AGACATCCTCTTTCCCTAGGCT
GTCT
GGATGTCTCTCCCTAGACCCAA
GGAA
ACAGCCTAGGGAAAGAGGATG
TCT
AAGAGGATGTCTCTCCCTAGAC
CCAA

CTIG675_FWD_T7
CTIG675_REV
CTIG675 FWD SEQ 3'5'
CTIG675 REV SEQ3'5' RT
CTIG675_GSP1
CTIG675_GSP2
CTIG675 FWD CLONING
CTIG675 REV CLONING
CCTIG675 FWD/Tc1

CTIG675
Cloning
Add Tc1
under
tetracycline
Add Tc2
promoter
Add Tc3
CTIG684
Northern

CTIG684
5’3’ SEQ

CTIG684
5’RACE

CTIG684_FWD
CTIG684_REV_T7
CTIG684 REV SEQ 3'5' RT
CTIG684 FWD SEQ 3'5'
CTIG684_GSP1
CTIG684_GSP2
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Table 2-1 continued.
Application/
Primer Name
Use

Sequence

CThctA FWD Infusion
Test SEQ
Cloning

Test SEQ Infusion REV_CAT
Test SEQ Infusion REV_tev
Test SEQ Infusion REV_ccdB
CcdB_CAT FWD Infusion
ccdB REV Infusion

CAT FWD Tc1+StuI
CAT/ccdB
CAT FWD Tc2

CAT_Tc FWD Infusion
CAT REV
CAT FWD Infusion
CAT Rev Infusion
ccdB/CAT
Tc ccdB FWD1

Tc ccdB FWD2
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GATAGAGATACTAGGTAAAACT
GAAAAAAATAGTTTAAAACAA
CAACTAGAGGATATTTT
GATTTTTTTCTCAGGCATGAAA
AAATATCCTCTAGTTGTTGT
ATTTTCACCGCCAGGCATGAAA
AAATATCCTCTAGTTGTTGT
AACCTTAAACTGAGGCATGAAA
AAATATCCTCTAGTTGTTGT
TGCGATGAGTGGCAGCAGTTTA
AGGTTTACACCTATAAAAGAGA
TCCCCCGGGCTGCAGGAATTTT
ATATTCCCCAGAACATCAGGTT
AATGGCGTTT
ATCAGTGATAGAGATACTAGGC
CTGAGAAAAAAATCACTGGATA
TACCACCGTTGATATA
TCCCTATCAGTGATAGAGATTG
ACATCCCTATCAGTGATAGAGA
TACTAGGCCTGAGAAA
TGGCAATTCCGACGTGACGTTC
CCTATCAGTGATAGAGATTGAC
ATCCCTATCAG
CTGCCACTCATCGCAGTACTGT
TGTAAT
GAGAAAAAAATCACTGGATAT
ACCACCGTTG
CTGCCACTCATCGCAGTACTGT
TGTAATTCATTAAGCATTCTGC
CG
CAGTGATAGAGATACTAGGCCT
CAGTTTAAGGTTTACACCTATA
AAAGAGAGAGCCGTTA
TGATAGAGATTGACATCCCTAT
CAGTGATAGAGATACTAGGCCT
CAGTTTAAGGTTTACA

Table 2-1 continued.
Application/
Primer Name
Use

Sequence

Tc ccdB FWD3

ccdB/CAT

Tc FWD Infusion

ccdB REV Infusion CAT
Origin
Change

SC101* FW Infusion
SC101* REV Infusion
pZA24 Fwd

Sequencing

pBAD
Cloning

Tig144
Cloning

pZSC101&amp;15A REV
SEQ
TEV FWD INFUSION
LIBRARY
pBAD REV+RBS
tig FWD Infusion
tig REV Infusion
TEV REV CLONING

TEV for
Tig144
Cloning

TEV FWD CLONING2
TEV REV CLONING p15A

TEV for
pBAD
Cloning

TEV FWD CLONING for
BAD
TEV REV CLONING
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TCCCTATCAGTGATAGAGATTGA
CATCCCTATCAGTGATAGAGAT
ACTAG
CTGGCAATTCCGACGTTCCCTAT
CAGTGATAGAGATTGACATCCC
TATCAG
AGTGATTTTTTTCTCTATTCCCC
AGAACATCAGGTTAATGGCGTT
TTTGATGTCATTTTCGCGGT
ATCCGCCGCCCTAGACCTAGG
GGGACTCTGGGGTTCGAGAGCT
C
TGCGAAACGATCCTCATCCTGT
CTCT
AGGAGAGCGTTCACCGACAAA
CAACA
CCGCCCTAGACCTAGGACGTCT
GTGTGGAATTGTGAGCGGATA
TATCCTTTCTCCTCTTTAATGAA
TTCTGTGTGAAATTGTTATCCG
AGAGGAGAAAGGATAATGCAA
GTTTCAGTTGAAACCACTCAAG
GC
TGTTGATGAACGCATCAGAGTA
TCCAGCATGCCGTCAACGTCAG
AAACCCGTACCCTAGCATAGGC
TTGGTTATGCCGGTACT
ATGCGTTCATCAACAAGTTTGT
ACAAAAAAGCAGGCTCGGGAG
AA
GGAATATATCCCTAGCATAGGC
TTGGTTATGCCGGTACT
AGAGGAGAAAGGATAATGCGT
TCATCAACAAGTTTG
AAACCCGTACCCTAGCATAGGC
TTGGTTATGCCGGTACT

Table 2-1 continued.
Application/
Primer Name
Use
TEV for
pBAD
TEV REV CLONING p15A
Cloning

Sequence
GGAATATATCCCTAGCATAGGC
TTGGTTATGCCGGTACT

Lib Tc infusion/lib FWD
Lib Tc infusion/tev REV

Tctev/ccdB
_tev/CAT
Cloning

Lib ccdB infusion/tev FWD

Lib ccdB infusion/tev REV

Lib CAT infusion/tev FWD
Lib CAT infusion/lib REV
Tig144
StuI
Removal

tig144 REV StuIREMOVE
tig144 FWD StuIREMOVE
ccdB FWD1 ADDATG

CcdB Add
ATG

ccdB FWD2 ADDATG
ccdB FWD infusion ADDATG
ccdB REV BmgBI infusion
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CAGCTGGCAATTCCGACGTTCC
CTATCAGTGATAGAGATTGACA
T
AAAATACAGATTTTCACCGCCA
GGCCTAGTATCTCTATCACTGAT
GAAAATCTGTATTTTCAGAGTC
AGTTTAAGGTTTACACCTATAA
A
TCTGAAAATACAGATTTTCAGA
ACCTATTCCCCAGAACATCAGG
T
ATCTGTATTTTCAGAGTGGCGA
GAAAAAAATCACTGGATATACC
A
CGGGCTGCAGGAATTTTACTGC
CACTCATCGCAGTACTGTTGTAA
ACACGGCGGCCAAGGCCCTGAG
TGGTTTCAACTGAAACTTGCATT
ACCTATGAACTGTCGACTCGAG
CATAGCATTTTTATCCATAAGAT
TCAGGGCATGCAGTTTAAGGTT
TACACCTATAAAAGAGAGAGCC
CCTGGCGGTGAAAATCTGTATTT
TCAGGGCATGCAGTTTAAGGTT
GATAGAGATACTAGGCCTGGCG
GTGAAAATCTGTATTTTCAGGG
C
TATCTGACAGCAGACGTGCACT
GGCCAGGGGGATCA

2.6

ncRNA MAPPING USING 5’ RACE

5’ Rapid amplification of cDNA ends (5’ RACE) is a technique used to determine
the sequences at the beginning of RNA molecules; we used Super SMARTTMPCR cDNA
Synthesis Kit (Clontech, CA) to determine the 5’ ends of RNA. Briefly, RNA sample
(1.5 µg) was mixed with gene specific primer(s)-1(GSP-1) (Table 2-1 under 5’RACE
application) (84 pmoles total) and SmartOligo (84 pmoles), the mixture was heated to
65°C for 2 minutes. The reaction mixture was cooled to 42oC and mixed with reaction
buffer (5x), DTT (2 mM, final concentration), dNTPs (2mM final concentration), RNase
inhibitor (100 U, final concentration), and PowerScript Reverse Transcriptase (5 U, total)
to generate the first-strand cDNA. First-strand cDNA was then column purified using
NucleoSpin columns (Clontech, CA). cDNA was then amplified using Advantage II
PCR kit (Clontech, CA) according to manufacturers instructions, we used SmartOligo
primer and nested GSP-2 primers for amplification (Table 2-1 under 5’RACE
application), the nested primer was designed downstream of GSP-1 to increase
specificity. The reaction was titrated by removing 20 µl aliquots from the reaction
starting at cycle 15 and from every third cycle following to a maximum of 33 cycles.
Reaction products were resolved on TBE-PAGE gels (10%), stained with ethidium
bromide, visualized and excised from the gel for, cloning and sequencing (similar to 2.5
above).
2.7

NORTHERN BLOTTING

Northern blotting was performed using 10% TBE-PAGE-Urea gels for RNA
electrophoresis in 1 x TBE buffer. RNA was transferred by electro-blotting, using plate
electrodes, for 1 h at 50 V, using 1 x TBE buffer as transfer medium. Zeta-probe GT
nylon membranes (BIORAD, CA) were used for electro-blotting. Single-stranded biotinlabeled RNA Probes were prepared using a MAXIscript T7 Kit (Ambion, TX). Target
sequences were amplified by PCR using chlamydial DNA as a template and a minimal
T7 promoter sequence was added 5' to the anti-sense strand (Table 2-1 under Northern
application). The resulting PCR fragment was fractionated on agarose gels, extracted,
and used as a template for a larger scale PCR reaction. PCR product was purified and
was used as a DNA template for an in vitro transcription reaction using MAXIscript T7
kit (Ambion, TX) and biotin-16-UTP (Roche, IN). The reaction was carried out for 1 h at
37°C, DNase treated for 15 min at 37°C, then the reaction was stopped by addition of 1
µl 0.5M EDTA. Buffer components and excess NTPs were removed by gel filtration
using NucAway Spin Columns (Ambion, TX). Hybridization was carried out in
UltraHyb (Ambion, TX) medium overnight at 65°C. Blots were washed using
NorthernMax Low Stringency Buffer (Ambion, TX) at room temperature (2 x 5 min) and
with NorthernMax High Stringency Buffer (Ambion, TX) at 65oC (2 x 60 min). Northern
blots were developed using alkaline phosphatase and streptavidin according to
manufacturer’s protocols (BrightStarTM BioDetect, Ambion).
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2.8

GENERAL CLONING

For cloning we used two different systems, the first was the regular
restriction/ligation/transformation and the second was recombination/transformation;
recombination was more versatile in its use, as it was not generally connected to a
specific restriction site, it was fast and reliable.
2.8.1

LIGATION

For ligation we used Fast-Link™ DNA Ligation Kit (Epicentre, WI) where target
plasmid was linearized by single or double digestion using NEB restriction enzymes
(NEB, MA), plasmid was either dephosphorylated using FastAP™ Thermosensitive
Alkaline Phosphatase (Fermentase, MD) followed by ligation, or the plasmid was blunt
ended using T4 DNA Polymerase (End-It™ DNA End-Repair Kit, Epicentre) followed
by dephosphorylation for blunt end ligation. Insert was generally a PCR product, PCR
products were gel purified, and either digested overnight by the appropriate restriction
enzyme(s) for directional cloning or phosphorylated by T4 DNA Polynucleotide Kinase
and ATP (End-It™ DNA End-Repair Kit, Epicentre) followed by ligation.
The End-It™ DNA End-Repair Kit (Epicentre, WI) was used to convert DNA
with 5'-protruding and/or 3'-protruding ends to 5'-phosphorylated blunt-end DNA for
blunt-end ligation. The conversion to blunt-end DNA was accomplished by exploiting
the 5'→3' polymerase and the 3'→5' exonuclease activities of T4 DNA Polymerase, in
addition, the enzyme mix also contained T4 DNA Polynucleotide Kinase and ATP carry
out phosphorylation of the 5'-ends of PCR amplicons for subsequent ligation into a
cloning vector. The protocol was carried out as follows, DNA (up to 5 µg) was
resuspended (or eluted) in 34 µl TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA), 5 µl
aliquots of 10X Buffer (330 mM Tris-acetate pH 7.8, 660 mM K acetate, 100 mM Mg
acetate,5 mM DTT), ATP (10 mM), and dNTPs (2.5 mM each) were added to the DNA,
followed by 1 µl of T4 DNA Polymerase/T4 Polynucleotide Kinase Enzyme Mix. The
reaction mixture was kept at room temperature for 45 minutes followed by heat
inactivation at 70°C for 10 min followed by column purification (MiniElute, Qiagen).
Ligation was carried out by Fast-Link Ligation kit (Epicentre, WI), where 1.5 µl
of 10X Fast-Link Ligation Buffer (330 mM Tris-acetate pH 7.8, 660 mM K acetate, 100
mM Mg acetate,5 mM DTT), and 1.5 µl ATP (10 mM), were mixed with both vector and
insert, the reaction volume was continued to 14 µl with water, then 1 µl Fast-Link DNA
ligase (2U/µl) was added and the reaction kept at room temperature for 2 hour to over
night. In case the reaction was a blunt end ligation, the amount of ATP was modified to
0.75 µl. The reaction was heated at 70°C for 15 min then transformed into chemically
competent or electrocompetent E. coli. Calculation of insert and vector amounts used in
ligation reaction were calculated as follows, the ratio of insert size to vector size was
calculated and multiplied into the intended amount of vector to be used in nano grams
then multiplied by 5, this equation calculated the amount in nano grams of insert used for
ligation.
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2.8.2

RECOMBINATION

Recombination was carried out using In-Fusion™ Advantage PCR Cloning Kit
(Clontech, CA), recombination was used to join multiple pieces of DNA that have 15
bases of homology at their linear ends; recombination was typically used for fusing PCR
products into vectors or joining different PCR products in one molecule with certain
arrangement of DNA fragments dictated by the 15 base homology rule. Recombination
offered a cloning technique that did not require the use of restriction enzymes, ligase or
phosphatase.
The process first involved designing primers for insert amplification; the primers
added 15 extra bases to each end of the amplicon, these extra bases were overlapping the
ends of the linearized plasmid (Table 2-1 contains list of primers used for recombination
under In Fusion application). In case of blunt cutters (e.g. StuI, BmgBI, ScaI) and 5’
overhand cutters (AvrII, SalI, EcoRI) the 15 base overlap on the plasmid start at the
cleaved nucleotide. In case of 3’ overhand enzymes (AatII, SacI, KpnI), overlapping
starts at the double stranded area of the plasmid ends, upstream of the single stranded
staggered ends. Insert was amplified using Phusion™ High-Fidelity DNA Polymerase
(Finnzymes Oy, MS), followed by gel/column purification (MiniElute clean up kit,
Qiagen).
For recombining several PCR fragments together, all fragments were quantified
and mixed to keep the molar ratio 1:1 as calculated by size ratio and concentration. For
cloning an insert into a vector, the vector was digested for 3 hours to overnight with the
appropriate restriction enzyme(s); restriction time depended on the stability of the
enzyme in the reaction (NEB literature) and the units of enzyme used. Vector to insert
molar ratio was 0.5, the amounts from each was calculated based on size ratios and
concentrations. All recombining DNA fragments were mixed and volume was completed
to 7 µl with water, then 2 µl of 5X buffer were mixed followed by 1 µl In-Fusion
enzyme. The reaction mixture was then incubated at 37°C for 15 min followed by 15
min at 50°C. The reaction was stopped by adding 40 µl TE buffer then using 5 µl for
transformation.
2.9

PROTEIN GEL ELECTROPHORESIS AND WESTERN BLOTTING

We used the NuPAGE® Bis-Tris Electrophoresis System (Invitrogen, CA). It is a
neutral pH, discontinuous SDS-PAGE, pre-cast polyacrylamide mini-gel system. The
neutral pH 7.0 environment during electrophoresis results in maximum stability of both
proteins and gel matrix, providing sharp bands (Moos et al, 1988), samples were mixed
with 2.5 µl of 4X NuPAGE® LDS Sample Buffer (106 mM Tris HCl, 141 mM Tris base,
2% (Lithium dodecyl sulfate [LDS], 10% Glycerol, 0.51 mM EDTA, 0.22 mM SERVA®
Blue G250, 0.175 mM Phenol Red, pH 8.5). and 1 µl NuPAGE® Reducing Agent (500
mM DTT), water was added to complete the volume to 10 µl. Samples were heated at
70°C for 10 min and then loaded on the gel. Gels used were NuPAGE 4-12% Bis-Tris
Gels, 1X running buffer was prepared by diluting 20X NuPAGE® MES SDS Running
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Buffer (50 mM MES 50 mM Tris base 0.1% SDS 1 mM EDTA pH 7.3) and adding
500µl of NuPAGE® Reducing Agent (500 mM DTT) per 200 ml of 1X NuPAGE® MES
SDS Running Buffer. The precast gel and running buffer were loaded into XCell
SureLock. Mini-Cell according to manufacturer’s instructions; gels loaded with
preheated samples and protein Marker (BIORAD, CA) and were run at 200 volts for 1
hour. Gels were either stained or transferred to PVDF membranes for Western blotting.
Staining was carried out as follows, NuPAGE® Gels were stained with SimplyBlue
SafeStain (Invitrogen, CA), after electrophoresis, gels were placed in 100 ml of ultrapure
water and microwaved on High (950 to 1100 watts) for 1 minute, gels were then put on
an orbital shaker for 1 minute, the heating and shaking was repeated once more. Water
was drained and 20 mls SimplyBlue SafeStain was added and the gel was microwaved
again for 45 seconds to 1 minute, followed by shaking for 5 min, gels were washed with
100 ml of ultrapure water for 10 minutes on the shaker followed by 20 ml of 20% NaCl
for 5 minutes where it was stored refrigerated.
Transfer was carried out using XCell IITM transfer cassette was assembled
according the manufacturer’s manual, transfer was carried out using 1X Transfer buffer,
[20X NuPAGE® Transfer Buffer (25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA, pH 7.2)
50 ml, NuPAGE® Antioxidant 1 ml, Methanol 100 ml, Deionized Water 849 m)].
Electrotransfer was carried out at 30 volts for 1 hour. Membranes were blocked over
night using Blocking Buffer (1X TBS, 0.1% Tween-20, 5% w/v nonfat dry milk),
membranes were washed 4X15min using TBS-T (1X TBS, 0.1% Tween-20), followed by
incubation with the primary antibody diluted in the blocking buffer over night.
Membranes were then washed 4X15 min using TBS-T, then incubated with the HRPsecondary antibody diluted in blocking buffer for 3 hours, membranes were washed 4X15
min using TBS-T and developed by ECL (Abcam, MA), the result was visualized using
Kodak BioMax XAR Film (Fisher Scientific, PA).
2.10

FUNCTIONAL ANALYSIS OF CTIG270 IN A SURROGATE SYSTEM

To test the effect of expression of CTIG270 on ftsI, a system was constructed
where both ftsI and CTIG270 were cloned in two compatible medium copy number
plasmids and transformed into E. coli. ftsI was fused in frame to a 5’ FLAG-tag sequence
(N-DYKDDDDK-C) and cloned under the control of a lac promoter (from pCR2.1,
Invitrogen) Figure 2-1.
The FLAG-tag was added using PCR (Table 2-1 ftsI-FLAG Cloning and
CTIG270 Cloning). Cloning was carried out in a promoterless pSMART-LCAmp
(Lucigen, WI). PCR was used to add an FseI site to the 3’ end and 5’ end of the
promoter and the FLAG-tagged ftsI respectively. Both amplicons were digested over
night with FseI followed by ligation. The fusion product was then amplified by PCR and
blunt end cloned into pSMART-LCAmp. CTIG270 was cloned under the control of an
arabinose responsive promoter (pBAD) in pRANGER-BTB vector (Lucigen, WI). E. coli
transformed with both plasmids was induced with IPTG and/or arabinose. E. coli was
harvested and analyzed using Northern blotting for both mRNA and ncRNA.
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Figure 2-1 Scheme for testing the function of possible cis acting ncRNAs. The figure
shows 2 plasmid system, one carries a FLAG-tagged target gene under pLAC promoter
and the other carries the ncRNA under test controlled by pBAD promoter.
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Northern blotting demonstrated transcription and stability of both RNAs. FtsI protein
was also checked using Western blotting.
E. coli transformed with both plasmids was grown to an OD600 of 0.6. The culture
was split into three tubes. One tube was induced with arabinose (0.2%), the second tube
was induced with IPTG (1mM) and the third one was uninduced. All three tubes were
incubated at 37°C on a shaker for 2.5 hours. A sample was collected from each test
condition and cells were centrifuged. Bacterial cells were used to prepare RNA
(MasterPure, Epicentre) for Northern Blotting and protein for Western blotting.
Following sample collection each culture tube received the second inducer. The first tube
was induced with IPTG (1mM), the second tube was induced with arabinose (0.2%) and
the third tube was induced with both IPTG (1mM) and arabinose (0.2%). The culture
tubes were incubated at 37°C on a shaker for 2.5 hours and a second sample was
collected from each tube as previously mentioned. Culture tubes were incubated at 37°C
on a shaker for 2.5 hours and the third sample was collected as previously mentioned.
RNA and protein samples were resolved by gel electrophoreses and loading was
normalized using OD600 measurements. Protein samples were resolved on a NuPAGE
Bis Tris gel and transferred onto a PVDF membrane according to manufactures
instructions (Invitrogen, CA). Western blotting was carried out using the ProteoQwest™
FLAG Chemiluminescent Western Blotting Kit (SIGMA-ALDRICH, MO). RNA
samples used for CTIG270 detection were resolved on a 10% Urea PAGE gels, while
RNA samples for ftsI detection were resolved on a 1% formaldehyde agarose
(NorthernMaxTM, Ambion). RNA was then transferred to a Zeta probe GT Nylon
membranes according to manufacturer’s instructions (BIORAD, CA). Northern blotting
was carried out using biotinylated RNA probes specific to CTIG270 and ftsI.
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CHAPTER 3. DISCOVERY AND VALIDATION PHASE
3.1

3.1.1

CONSTRUCTION AND TESTING OF THE CHLAMYDIAL
INTERGENIC MICROARRAY

CONSTRUCTION OF THE CHLAMYDIAL INTERGENIC MICROARRAY

Using intergenic microarrays for determining ncRNA expression represents an
unbiased, hypothesis-neutral, and direct approach. We have designed and constructed a
GeneChip Custom Affymetrix microarray to determine the expression levels of ORFs
and untranslated elements in IGRs of C. trachomatis D (strain UW-3/CX) based on the
genomic sequence (Stephens et al, 1998).
The IGRs of the C. trachomatis D and the C. pneumoniae AR-39 genomes that
were 50 nucleotides or more were represented on the microarray. IGRs were represented
as 25 nucleotides probes tiled head to tail on both strands. IGR probes present certain
problems in the design process. The defined nature of the target sequences (i.e. tandem
25’mers) greatly restricted the selection process, and target probe acceptance values had
to be lowered to a certain extent. The initial design submission returned 82% of the tiled
probes as acceptable. To increase the flexibility of the algorithms selection process for
the remaining 18% of the target regions were expanded by 5 nucleotides at the 5’ and 3’
ends (i.e. target sequence became 35 nucleotides) resulting in a coverage of 92% of the
intergenic regions. This process was repeated by extending the remaining 8% region by
10 nucleotides in the 5’ and 3’ direction, resulting in 98% coverage of the intergenic
region (6695 probes). Certain probes could not be synthesized (145) due to secondary
structure or synthesis step problems. None of these were adjacent and therefore the
transcriptional status of these regions can be conditionally estimated by comparison to
flanking probes. The need to lower acceptance values for probe design in the IGRs made
the synthesis of MM probes questionable and, at the suggestion of the Affymetrix Design
Team; these probes were not included on the microarray. The expression results for the
IGRs have therefore been interpreted in a contextual manner and require experimental
controls.
An example of the microarray results are shown in Figure 3-1 in which the
fluorescence intensities of the microarray have been converted to a genomic “Array
Layout” display for ORFs and IGRs (Belland et al, 2003b). The region displayed in
detail is the intergenic region containing CT269 (murE) and CT270 (ftsI) and a potential
cis-acting ncRNA (CTIG270) that is expressed downstream of ftsI on the opposite strand.
The display in Figure 3-1 shows each ORF as a single filled circle on the upper or lower
strand depending on the orientation of the ORF (color represents the mean fluorescence
intensity for the multiple ORF probes) while the intergenic region is shown as several
double circles each representing a single 25 nucleotides probe on one of the two DNA
strands (colors represent fluorescence intensity).
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Figure 3-1 The MPAUT-1 microarray and a schematic display of experimental data.
The figure shows the actual scanner-generated image of the array (the left hand side) and
the array layout (right hand side): which is a computer generated image converting
fluorescence intensities to colors of different shades (green being lowest expression and
red being highest expression values). The figure also shows a magnified segment of the
chromosome detailing CT269, CT270 and a possible antisense RNA to CT270. Each
ORF is represented by a circle, the direction of the ORF dictates whether the circle is
located on the upper line (upper strand) or on the lower line (lower strand). The IGR is
represented by a string of circles on both lines, each circle represent a single 25 mer
probe.
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3.1.2

TESTING THE MICROARRAY

Intergenic microarrays pose a challenge because of probe quality, the limited
space available within the target sequence for maneuvering, and getting a probe with
good hybridization parameters. Preliminary experiments were performed using C.
trachomatis D chromosomal DNA. Chromosomal DNA offered a linear representation
of all sequences on the array at a 1:1 ratio. We used labeled chromosomal DNA to check
the intergenic microarray probe quality. DNA from C. trachomatis D was fragmented
via partial DNase I digestion (Amersham, UK) and Biotin end-labeled with terminal
transferase (Invitrogen, CA). The DNA array result summary is shown in Table 3-1.
ORFs had a mean fluorescence intensity of 2008 arbitrary fluorescence units and
a standard deviation of ±244. This tight distribution is the consequence of each ORF
being represented by 11-8 probe pairs (PM and MM) and the fluorescence represented
the mean value according to the equation ∑ 𝑃𝑃𝑃𝑃 − 𝑀𝑀𝑀𝑀⁄11. On the other hand, probes
representing IGRs had a mean fluorescence intensity of 2953 units and a standard
deviation of ±1394. The apparent wide range of the IGR results was because the
fluorescence of each probe was reported as an individual event. The DNA array analyses
indicated that 399 out of 6695 (5.9%) probes in IGRs had a fluorescence value less than
500. The lower quality of these probes was taken into consideration when examining
RNA microarray results.
3.2

RNA PREPARATION

RNA prepared from Chlamydia-infected cells is composed of a mixture of host
RNAs (rRNA, mRNA, tRNA) and bacterial RNAs (rRNA, mRNA, tRNA) in which the
former represents the vast majority. To enrich for bacterial mRNA we tested procedures
that selectively remove host mRNA and bacterial and host structural RNAs (rRNA and
tRNA) but retained small sized RNA species. Three enrichment procedures were carried
out and compared using the MPAUT-1 intergenic microarray (summarized in Figure
3-2).
The first condition (labeled 1 in Figure 3-2) was a process the involved the
removal of host mRNA by treatment with a dC10T30 oligo-nucleotide linked to
polystyrene-latex particles (OligoTexTM, Qiagen). The second condition involved
Table 3-1 C. trachomatis D-DNA microarray results summary.
Parameter
Mean fluorescence intensity
Median fluorescence intensity
Standard deviation
Highest value
Lowest value
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ORFs
2008
2004
244
2981
788

IGRs
2953
2892
1394
8015
500

Figure 3-2 Enrichment procedures for chlamydial RNA for use with MPAUT-1.
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the removal of host mRNA and structural RNAs (labeled 2 in Figure 3-2) using “capture”
oligonucleotides coupled to magnetic beads that remove polyadenylated mRNA and 18S
and 28S rRNAs (capture oligonucleotides are complementary to 18S and 28S sequences,
MICROBEnrichTM, Ambion). The third condition was an extension of the second
procedure (labeled 3 In Figure 3-2) and involved further removal of bacterial 16S and
23S rRNAs using capture oligonucleotides (complementary to 16S and 23S rRNA
sequences of C. trachomatis, MICROBExpressTM, Ambion).
The MPAUT-1 microarrays were used to compare the effect of these various
enrichment methods on both sensitivity and specificity of the microarray. Equivalent
quantities of RNA were used for random-primed cDNA synthesis, fragmentation with
DNase I, and labeling with biotin using T4 Terminal transferase (according to Expression
and Analysis Technical Manual, Prokaryotic Probe Processing, Affymetrix).
Comparison of different enrichment schemes indicated that all conditions showed
acceptable levels of sensitivity. Sensitivity was estimated based on the number of ORFs
flagged as present in each experiment (814, 760 and 864 for the three treatment protocols
respectively). As shown in Figure 3-3, comparing the correlation coefficient of ORFs’
fluorescence values for each treatment against the MICROBExpressTM protocol showed
high levels of reproducibility, (OligoTexTM to MICROBExpressTM had an R2 = 0.8228
and MICROBEnrichTM to MICROBExpressTM had an R2 = 0.8764).
The “scaling factor” calculation was used as an estimate of enrichment. Scaling is
a mathematical technique used by GeneChip Operating Software (GCOS) to minimize
differences in overall signal intensities between two or more arrays. This mathematical
normalization allowed for a reliable detection of biologically relevant changes between
different samples. GCOS calculates the overall intensity of an array by averaging the
intensity values of a preset reference probe matrix (in this case we set chlamydial ORFs
as the reference matrix). The average intensity of the array was then multiplied by the
scaling factor to bring it to an arbitrary target intensity value (500). Thus, scaling allows
a number of experiments to become normalized to one target intensity, and direct
comparisons between any two experiments can be carried out. The scaling factor
provided a measure of the brightness of the array. This measure reflected the availability
of bacterial mRNA in matched test samples. By setting the reference probe matrix to
chlamydial ORFs a high scaling factor can then be interpreted as a dim array, which
might reflect lower abundance of chlamydial mRNA. On the other hand, low scaling
factors reflect a bright array; an indication of abundant chlamydial mRNA on the array.
The calculated scaling factors for every enrichment scheme reflected the relative
enrichment of bacterial mRNA in each sample as follows; for OligoTexTM and
MICROBEnrichTM it was 25.8 and 36.5 respectively, while for MICROBExpressTM it
was 2.5977. For this reason we chose the MICROBExpressTM enrichment scheme for the
following experiments.
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Figure 3-3 Comparison of RNA purification protocols for use with the MPAUT-1
microarray.
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3.3
3.3.1

IDENTIFICATION OF C. trachomatis ncRNAs

GUIDELINES FOR IDENTIFICATION OF C. trachomatis ncRNAs

Potential ncRNAs were named using the IGR number corresponding to the
downstream ORF using the CT numbers defined by Stephens et al, 1998 e.g. an ncRNA
located upstream of CT241 is referred to as CTIG241. C. trachomatis D RNA collected
from 40 h post infection (PI) samples was processed and used to characterize the
expression of ncRNAs. Identification of potential ncRNAs was based on a number of
guidelines including: i) sequential probes showing simultaneous expression (3 or more),
ii) high levels of fluorescence from at least one of the IGR probes (>1000), iii) relatively
high G+C ratio of the expressed region (elevated G+C ratios have been shown to predict
biological function (Zhang et al, 2004)), iv) presence of rho-independent terminators at
the end of the ncRNA, v) location with respect to flanking ORFs, and vi) genomic
conservation with other chlamydial species. An example of this type of analysis is shown
in Figure 3-4 in which the expression of a potential ncRNA (CTIG241) is compared to
expression of tRNA-Leu-2. The IGRs and flanking ORFs are shown with corresponding
expression levels and G+C ratio.
3.3.2

RESULTS OF MICROARRAY SCREENING

As shown in Table 3-2, House-keeping ncRNAs were used as a validation tool for
microarray results. We were able to detect all 37 tRNAs predicted in the genome of C.
trachomatis D (including the tRNA-Leu-2 in Figure 3-4). In addition, a number of highly
conserved ncRNAs found in other bacterial genera were also detected. These included: i)
tmRNA (CTIG019), associated with the release of stalled ribosomes and the
incorporation of a short peptide tag that targets the partial protein product for degradation
(Withey and Friedman, 2003), ii) 4.5S RNA (CTIG255), which forms part of a
ribonucleoprotein complex that plays a role in protein secretion (Poritz et al, 1990), iii)
M1 RNA (CTIG399), which forms the catalytic subunit of RNase P, involved in 5’ tRNA
processing (Kleineidam et al, 1993) and iv) and both 5S rRNAs (CTIG740 and CTIG750)
which is involved in the ribosome assembly (reviewed in Gongadze et al, 2008).
Microarray analysis showed that C. trachomatis D expressed 34 other intergenic
sequences that met the guidelines for ncRNA identification. These included ncRNAs that
could be classified as cis-acting antisense molecules in that the expressed transcript
overlapped the 3’ end of a transcript from an annotated gene in the opposite direction (as
shown for CTIG270 ncRNA and ftsI gene in Figure 3-1, and for CTIG153 ncRNA and
CT152 [lolD]). Potential intergenic ncRNAs were also found that fit into the category of
trans-acting molecules. Table 3-2 summarizes the Northern blot results for all 34
potential ncRNAs (14 potential ncRNAs were detected by Northern blotting). An
average G+C ratio of 0.41 was selected as a threshold ratio for ncRNAs. This ratio was
selected because this was the average G+C ratio for C. trachomatis D chromosome. Out
of the 14 transcripts detected by Northern blotting 3 ncRNAs had an average G+C
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Figure 3-4 Guidelines for identification of the ncRNAs. Identification involved the
expression levels of a contiguous intergenic regions, G+C ratio, and position with respect
to flanking ORFs. Shown here is a comparison of the CTIG241 potential ncRNA and the
tRNA-Leu. Threshold levels for inclusion are shown as pink bars across the tiled
intergenic regions.
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Table 3-2 Results of the 40h PI microarray experiment showing all known ncRNAs
(tRNA, tmRNA, 4.5SRNA, 5SRNA, M1RNA, and ihtA) in addition to potential
ncRNAs.
Name
37tRNAs
tmRNA
4.5S RNA
5S rRNA
ihtA
M1 RNA
CTIG153
CTIG241
CTIG270
CTIG327
CTIG356
CTIG360
CTIG498
CTIG504
CTIG582
CTIG643
CTIG684
CTIG805
CTIG809
CTIG857
CTIG001
CTIG059
CTIG072
CTIG181
CTIG195
CTIG237
CTIG256
CTIG268
CTIG323
CTIG433
CTIG442
CTIG444
CTIG449
CTIG592
CTIG660
CTIG663
CTIG775

Approx.
Size
75-100
525
100
125
150
400
75
75
100
250
225
200
100
75
200
650
100
200
125
225
125
50
175
75
200
325
150
175
225
75
200
125
125
150
125
250
175

Class1

A.F.U.2 Northern

tRNA
PI
PI
Ribosomal
trans/3'UTR
PI
cis
trans
cis
trans
trans/UTR
trans/Riboswitch
trans/3'UTR
trans/3'UTR
trans
trans
trans
trans
trans
trans
trans
trans
trans
trans
trans
trans
trans
trans/5'UTR
trans
trans/5'UTR
trans/3'UTR
cis
trans
trans
trans/3'UTR
trans
trans
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25927
24598
15917
32001
9938
20235
884
6073
994
1926
7238
4533
3976
3959
2135
7279
1420
5677
748
772
1396
1281
2780
4001
1852
6378
1941
5765
4479
2723
2339
3620
4248
1335
14347
2784
2877

NA
NA
Positive
NA
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

Rho Average
Indpt3 G+C Ratio
0.51
NA
0.45
−
0.51
−
0.47
−
0.46
√
0.43
−
0.52
−
0.53
−
0.36
−
0.37
√
0.44
0.43
√
0.46
√
0.42
√
0.39
√
0.41
√
0.47
√
0.37
−
0.44
−
0.45
−
0.35
−
0.57
−
0.39
−
0.36
−
0.4
−
0.4
−
0.38
−
0.43
−
0.41
−
0.44
−
0.4
−
0.37
−
0.49
√
0.36
−
0.43
−
0.44
−
0.39
−

Table 3-2 continued
Name
CTIG813
CTIG864

Approx.
Size
225
125

Class1

A.F.U.2 Northern

trans
trans

1364
19393

Negative
Negative

Rho Average
Indpt3 G+C Ratio
0.34
−
0.41
−

Approximate sizes are based on the array, the potential functional class, the average
fluorescence of the probes representing the ncRNA, presence of Rho independent
terminator, and the average G+C ratio across the region in question.
1
Class of ncRNA refers to its presumed mode of action. PI is protein interaction.
2
A.F.U. Average Fluorescence Units.
3
Rho indpt is Rho Independent terminator as analyzed by www.softberry.com.
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ratio bellow 0.41. All other tested ncRNAs and house-keeping ncRNAs had an average
G+C ratio between 0.43 and 0.53.
Interestingly, 8 of these 14 ncRNAs had a potential rho independent terminator.
ncRNAs that were not detected by Northern blotting generally had lower G+C ratio (11
out of 20 were bellow 0.41), and 1 had a potential rho independent terminator.
Collectively these results pointed to the potential expression of new, previously
uncharacterized, RNA molecules during the normal developmental cycle of C.
trachomatis D.
3.3.3

VALIDATION OF ncRNA EXPRESSION

RNA samples were DNAsed (TurboDNAse, Ambion) and resolved on 10%
UREA PAGE gels (Criterion, BioRad), transferred onto nylon membranes (GT-ZetaProb GT, BioRad), and probed with biotin-labeled single stranded RNA probes. The
probes were prepared by adding a T7 minimal promoter sequence to PCR amplified IGRs
(Northern Blotting, section 2.7 above). The microarray was used as guide to determine
the orientation of the potential ncRNA (thus decide which strand to probe) and to narrow
the target area, thus preventing interfering signals from nearby genes and/or tRNAs. T7
PCR products were then subjected to an in vitro transcription reaction containing 16UTP-BIOTIN (Roche Applied Science, IN). The product was then DNAsed and stored at
-80°C. By selecting the correct primer for the T7 promoter and by decreasing the size of
the PCR to a minimal size (150-200 bases), we were able to probe every potential
ncRNA. The Blots were then visualized by streptavidin bound alkaline phosphates and
treated with the substrate, CDP-Star according to manufacturer’s instructions (BrightStar,
Ambion). Table 2-1 shows a list of primers used for probe preparation and Northern
blotting.
A subset of the potential ncRNAs that were verified by Northern blotting (Figure
3-5) included CTIG153, CTIG241, CTIG270, CTIG327, CTIG356, CTIG360, CTIG498,
CTIG504, CTIG643, and CTIG684. Figure 3-5 also showed the results of some known
ncRNAs including tRNA leu, 4.5S RNA, M1 RNA, plasmid antisense transcripts (Fahr et
al, 1992), and ihtA (Grieshaber et al, 2006). ihtA has been shown to translationallysilence expression of the chlamydial histone HctA in a heterologous E. coli co-expression
system. A schematic of the chromosomal arrangement of the locus for each ncRNA is
shown in Figure 3-6.
CTIG153 had two products ranging in size from 120 to 170 nucleotides (Figure
3-5). The chromosomal locus in Figure 3-6 showed that CTIG153 is located on the lower
strand running towards CT152. Upon further inspection, a rho independent terminator
was detected 14 bases upstream from the CT152 stop codon creating a possible overlap of
60 nucleotides between the ncRNA and CT152 (14 bases upstream of the terminator plus
46 nucleotides that form the terminator stem loop). This architecture is strongly
suggestive of an antisense mode of action. Moreover, the fact that the Northern blot
showed two bands suggest that CTIG153 is processed in the course of interaction with
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Figure 3-5 Northern blotting of potential ncRNAs from C. trachomatis at 40 h PI.
House-keeping small RNAs (RNase P, 4.5S RNA, and tRNA-Leu-2) and several novel
(CTIG153, 241, 270, 327, 356, 360, 498, 504, 643, and 684) and previously described
IhtA (Grieshaber et al, 2006) and plasmid antisense transcripts (Fahr et al, 1992) RNAs
are shown. Chlamydial ncRNAs were probed with strand-specific, biotin-labeled probes
using equivalent amounts of non-enriched RNAs.
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Figure 3-6 A schematic of the chromosomal locus for each ncRNA shown with the two
flanking genes. Black arrowheads represent ncRNA and gray arrowheads represent
tRNAs.
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CT152. The small band might be a partially processed RNA that is missing its 3’ end. In
order to prove this hypothesis another set of probes were designed. One overlapped the
5’ end of CTIG153 and the other overlapped its 3’ end. Northern blotting showed that
only the 5’ probe was able to identify both bands while the 3’ probe identified the large
product only (data not shown).
CTIG241 is located upstream of CT241. Generally ncRNAs located upstream of
genes on the same strand might be 5’UTR for those genes. CTIG241 is located about 50
nucleotides downstream of CT240 and 250 nucleotides upstream of CT241. Although no
obvious rho independent terminator was located in the vicinity of the ncRNA; a classical
stem loop ending in a group of Us was located at the 3’ end of the ncRNA. This potential
terminator was not reported by the software (www.softberry.com) because it was
destabilized by two bulges. The software might have assigned this terminator an inferior
score. Analysis of the G+C ratio in this locus shows an unusual bias towards a high the
G+C ratio in the ncRNA location (Figure 3-4). CTIG241 does not overlap with flanking
genes which makes it a potential trans-acting ncRNA.
CTIG270 deviated from the guidelines of selection of ncRNAs in several aspects.
It had a low G+C ratio (0.36), and had no terminator structure within the IGR or in the
downstream gene (Table 3-1). The sequence directly upstream of CTIG270 contained
several repeats suggesting a protein-DNA binding site(s). The signal detected on the
Northern blot for CTIG270 was considered the weakest in all the examined ncRNAs.
The chromosomal arrangement showed that CTIG270 ran on the upper strand and
overlapped the 3’ end of CT270 (ftsI). The architecture suggests an anti sense
mechanism of action that affects the stability of ftsI. On the contrary to CTIG153, a
single major product was detected for CTIG270. This was possibly due to complete
degradation of the ncRNA when it interacts with its target gene. Comparing the
chromosomal locus in both C. trachomatis and C. muridarum revealed that the locus in
C. muridarum contains an annotated ORF in place of CTIG270. The annotated ORF was
located on the upper strand opposite to the flanking genes. Its first ATG overlapped
murE coding sequence by 15 nucleotides (named murG in C. muridarum) and ends 7
nucleotides before the ftsI stop codon. The presence of this ORF led us to investigate if
CTIG270 as identified in C. trachomatis represented a pseudogene. In order to address
this question, we synthesized a series of ~200 nucleotide probes spaced over the IGR
from the start of murE to ~500 nucleotides inside ftsI, (Table 2-1 primers listed under
Probe -219 to -18, Probe -106 to +67, Probe +83 to +264, and Probe +275 to +494,
numbering starts at CTIG270 TSS as +1) Northern blot analyses indicated that CTIG270
was located 100-200 nucleotides upstream of ftsI stop codon, and about 100-200
nucleotides downstream of murE start codon. Probe -219 to -18 covered the area where
the possible pseudogene would be located. This probe failed to detect CTIG270.
CTIG327 is located 200 nucleotides downstream of CT326.2 and 250 nucleotides
upstream of CT327. All three genes were located on the lower strand and in the same
orientation. There was a rho independent terminator located at the end of CTIG327.
Upon examining the sequence within this intergenic region, a possible unannotated ORF
of 204 nt was found overlapping CTIG327. The unannotated ORF ended 42 nt
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downstream of the rho independent terminator. We investigated whether the product
detected on the Northern blot represented CTIG327 or represented the unannotated ORF.
Two probes were designed. One overlapped the 5’ end of the message and the other
overlaps the region downstream of the terminator. Northern blotting result showed that
the product could only be detected when using the probe overlapping the 5’ end. This
result showed that the product belongs to the ncRNA not the unannotated ORF (data not
shown).
CTIG356 and CTIG360; both had similar chromosomal arrangements. Their
arrangements suggested that they might be 5’ UTRs for there upstream genes (CT355 and
CT359 respectively). Table 3-2 denoted CTIG360 as a potential riboswitch.
Riboswitches are RNA elements that undergo a shift in structure in response to binding of
a small molecule. Such structural shifts affect stability and or translatability of the
message. These elements are encoded within the transcript they regulate. They act in cis
to control expression of the coding sequence within that transcript. Riboswitch RNAs
control a broad range of genes in bacterial species, including those involved in
metabolism, uptake of amino acids, cofactors, nucleotides, and metal ions (reviewed in
Henkin, 2008). CTIG360 was located directly upstream of CT359, which is a bioY gene.
Orthologue of bioY in Rhodobacter capsulatus was able to confer biotin uptake
phenotype to a mutant E. coli strain that was deficient in biotin uptake (Hebbeln et al,
2007). Latter results will add more to this discussion.
CTIG498 and CTIG504 overlapped the 3’UTR of CT497 and CT504
respectively. Both genes were reminiscent of ihtA chromosomal arrangement. Both
ended in a rho independent terminator. Moreover, CTIG504 and ihtA have a tRNA
directly downstream of the rho independent terminator.
CTIG643 and CTIG684 were located in the middle of the IGR, on the upper
strand and in the same direction as the downstream genes. Both ended in a rho
independent terminator. CTIG643 showed two products on the Northern blot. Two
probes overlapping the sequences flanking the terminator were prepared. Northern blot
showed that the small product represented the sequence upstream of the terminator, and
the larger product contained both sequences upstream and downstream of the terminator.
CTIG684 On the other hand, was represented by several small products around 50-70
nucleotides. RNA probes upstream and downstream of the terminator showed that all
products represented sequences upstream of the rho independent terminator.
3.4
3.4.1

DISCUSSION

USE OF THE TILING MICROARRAY PLATFORM

The primary hurdle facing ncRNA discovery is the absence of a clear signature
element(s) in the primary genome sequences. Preset assumptions of possible signature
sequences have been implemented to find candidate ncRNAs. The majority of confirmed
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ncRNAs were identified primarily by comparative sequence analysis to identify
conserved elements in IGRs. Additional sequence signatures including intergenic
promoter elements, sequences predicted to form stable RNA secondary structures, and
intergenic rho-independent terminator elements have also been used for the screening of
candidate ncRNAs (Argaman et al, 2001; Rivas and Eddy, 2001a; Rivas et al, 2001b;
Livny et al, 2005).
In such a new field there still not enough data that conclusively mandate using the
aforementioned signature elements as the main method of screening for ncRNAs. In
addition, the less biased shotgun cloning approach has identified highly expressed
ncRNA candidates in E. coli that were missed by comparative analyses (Vogel et al,
2003).
We have used a different unbiased strategy to identify ncRNAs in C. trachomatis.
In this strategy we used a custom tiled Affymetrix microarray combined with an
experimental protocol and analysis scheme optimized for ncRNA detection. We first
scored the quality of each individual intergenic probe by hybridizing chromosomal DNA
to the microarray. We then tested RNA samples, and analyzed each IGR for
simultaneous high levels of florescence of 3 or more consecutive probes. Each potential
IGR was further inspected for rho independent terminators, localized high G+C ratio,
conservation among various sequenced chlamydial species, and finally analyzed by
Northern blotting using strand specific RNA probes.
The E. coli high-density microarrays were used to identify ncRNAs. Both total
RNA and RNAs isolated by co-immunoprecipitation with the RNA binding protein, Hfq
were used for screening (Tjaden et al, 2002; Zhang et al, 2003; Hu et al, 2006). Highdensity microarrays, combined with comparative genome analysis, had led to the
identification of mostly growth phase dependent ncRNAs in E. coli and Staphylococcus
aureus and of ncRNAs whose expression is under the control of sporulation in Bacillus
subtilis (Wassarman et al, 2001; Pichon and Felden, 2005; Silvaggi et al, 2006).
Although DNA microarrays are a valuable tool for both identification and transcription
profiling of ncRNAs it, like all other approaches, bears some caveats. One of the most
challenging aspects of this technique is the preparation and labeling of RNA samples.
The small size and structure of ncRNAs make these transcripts poor substrates for
amplification and labeling. In addition, shorter ncRNAs (< 50 nucleotides) might be
harder to detect, especially if the probes were arranged head to tail with no overlap.
Therefore, short ncRNAs and ncRNAs that are highly structured and/or modified were
likely to be missed. This phenomenon was observed in case of CTIG153. Its average
fluorescence on the array was 884 (Table 3-2) while the Northern blotting showed high
level of transcription (exposure time for developing the Northern blot was seconds). A
novel detection method employing antibodies specific for RNA–DNA hybrids
circumvented the problem of labeling and was shown to improve sensitivity (Zhang et al,
2003; Hu et al, 2006), and probably would be worth checking for future microarray
experiments, this method was also recommended by S. Gottesman (Personal
communication, 2005).
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3.4.2

PROBE QUALITY AND RESULT INTERPRETATION

DNA microarray result uncovered considerable variations in probe sensitivity.
This observation was confounded by the absence of mismatch probes. It was
recommended by the Affymetrix design team to disregard inclusion of the MM probes. It
was reasoned that since IGR probes were tested individually, the statistical package that
calculates the average fluorescence for each gene would not be fully functional and there
was no need to include MM probes. Moreover, elimination of MM probes increased the
available features on the microarray and increased the allowed synthesis steps by 4
rounds. Comparing the MPAUT-1 with the high density microarray for E. coli (Tjaden et
al, 2002), we noticed the difference in probe selection protocol. MPAUT-1 probes were
arranged head to tail with no intentional overlaps. On the other hand, the high density
microarray probes were selected every 4 nucleotides. Whether this denser probe
selection scheme offered more validity for the results is unknown, but the high density
version offered a worthwhile alternative. Tjaden et al, 2002 preformed a similar set of
quality control tests for the IGR probes. Initial analysis of the data across all experiments
(total of 26 microarrays) showed a range of hybridization affinities for different probes.
2671 probes were eliminated from the analysis for which there was evidence of
significant cross-hybridization or other non-specific hybridization. Bad probes were also
determined by hybridizing E. coli genomic DNA labeled directly with terminal
transferase to the microarray and eliminating the probes that failed to meet expected
values.
Zhang et al, 2003 developed a rating system for analyzing microarray data. IGRs
were rated 5 if the average probe florescence was ≥10,000, an average fluorescence
intensity of ≥5000 was rated 4, an average probe florescence of ≥1000 was rated 3, and
finally an average probe florescence of ≥200 was rated 2. Candidate IGRs were analyzed
by Northern blotting.
The field of genome sequencing and genome wide transcriptome sequencing is
getting faster, more efficient, and more cost effective by time. Lately a new technology
has emerged where whole transcriptomes were sequenced in a bead based emulsion PCR.
The cDNA was ligated to adapters, clonally selected on the beads and amplified via
emulsion PCR. Several samples could be pooled (up to 20 samples) using bar coded
adapters and all the beads were deposited on slides and sequenced in parallel by repeated
rounds of hybridization and ligation of fluorescently labeled di-base probes followed by
cleavage and detection (The SOLiD™ 3 System, Applied Biosystems). This system had
the advantage of generating actual sequences as readouts rather than fluorescence. Based
on the number of times a sequence appeared the relative abundance of the message was
calculated. The SOLiD technology, being non sequence dependent, also had the
advantage of getting sequences of previously un-identified transcripts. This sequencing
based detection offered a solution to a problem that was seldom addressed using other
techniques. It offered an easier way to detect antisense ncRNA that are totally buried
within annotated genes. Future experiments are being planned involves using this
platform.
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3.4.3

POTENTIAL ncRNAs IN C. trachomatis D

Comparative genomics of ncRNAs in bacterial genomes found that on average,
ncRNAs are found in approximately 30% of IGRs of each genome sequence. Of these,
25.7% are conserved among three or more organisms. Approximately 60% of the
conserved ncRNAs are not located in orthologous IGRs, implying that ncRNAs may be
shuffled in genomes (Luban and Kihara, 2007). The potential ncRNAs in Chlamydia
were located 5’and 3’ to annotated genes. Since no functions have been assigned to any
of the ncRNAs (except ihtA), there remains the possibility that they represent processed
5’ and 3’ RNAs. Some established ncRNAs in other bacteria were located in the vicinity
of flanking genes. 6S RNA, a major regulator of E. coli σ70, was produced as a part of a
longer message (Trotochaud and Wassarman, 2004; Wassarman, 2007). Another
example is RNAIII, a bifunctional molecule that encodes the δ-hemolysin protein in its 5′
end while it also acts as an ncRNA (Janzon et al, 1989). Examining the chlamydial
chromosome revealed several indications that several functional genetic elements are
packed within a limited space. For example, Chlamydia has 6 tRNAs (out of 37) that
were located just 24 to 37 nucleotides upstream of genes on the same strand. In order for
the transcripts of these genes to be independent, a distance of at least 45 nt was required
between them and the closest tRNA (35 nucleotides promoter and shine Dalgarno
sequence). In addition 8 pairs of tRNAs belonged to bicistronic operons. Moreover, the
only known chromosomally encoded ncRNA in Chlamydia (ihtA) was located 16
nucleotides downstream of yscC and directly upstream of a tRNA. These observations
indicated that Chlamydia has limited space to fit several genetic elements within a
confined spac.
3.4.4

CTIG270 AND ftsI

In E. coli, ftsI was involved in the biosynthesis and degradation of the murein
sacculus and peptidoglycan. It was specifically localized to the division septum.
Invagination of the cytoplasmic membrane was accompanied by the synthesis of
peptidoglycan at the leading edge of the invagination. This septal specific peptidoglycan
biosynthesis occurred in two stages (Woldringh et al, 1987; Wientjes and Nanninga,
1989; Nanninga, 1991). An early stage that is penicillin insensitive and a later stage that
is sensitive to penicillin and requires PBP3, the product of the ftsI gene (Botta and Park,
1981; Spratt, 1977).
Identification of CTIG270 as a potential antisense regulator of ftsI added more
questions to an already puzzling situation (1.2.6 above). dicF an ncRNA inhibited the
translation of ftsZ (Faubladier and Bouche, 1994; Tetart and Bouch, 1992). It was
established as the smallest ncRNA that had an assigned function (53 nucleotides).
Probably Chlamydia which lacks ftsZ was using another ncRNA to control another key
enzyme in peptidoglycan synthesis. To our knowledge there was no precedence for an
antisense RNA that regulates a penicillin binding protein. Whether CTIG270 represents a
key molecule in regulating cell division remains to be determined. Another question was
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the involvement of other PBPs encoded by the chlamydial genome in this regulatory
circuit.
Sequence inspection revealed more information about this ncRNA. CTIG270 had
a 15 nucleotides complementarity to a sequence 200 nucleotides downstream of ftsI start
codon. Similar finding was observed in C. muridarum CTIG270/ftsI orthologues. The
result of binding of CTIG270 to ftsI could either be degradation or stabilization of ftsI. In
E. coli gadY ncRNA was shown to overlap the 3' end of gadX gene. This overlap region
was found to be necessary for the gadY-dependent accumulation of gadX mRNA. It was
suggested that during the stationary phase gadY base paired with the 3'-untranslated
region of gadX mRNA and conferred increased stability. This allowed gadX mRNA to
accumulate and increased the expression of downstream acid resistance genes (Opdyke et
al, 2004; Tramonti et al, 2008).
3.4.5

CTIG360 AND bioY

Biotin represents an important metabolite for both eukaryotes and prokaryotes.
Biotin is a water-soluble vitamin that participates as a cofactor in gluconeogenesis, fatty
acid synthesis and branched chain amino acid catabolism. It functions as the carboxyl
carrier for biotin-dependent carboxylases (Gravel and Narang, 2005). Bacteria get biotin
from two main sources, de novo synthesis (Pai and Lichstein, 1965; Gloeckler et al,
1990; Bower et al, 1996; Flint et al, 1997) and transporter based uptake (Pai, 1973;
Guillen-Navarro et al, 2005; Hebbeln et al, 2007). In these systems the amount of biotin
in the cell was controlled by transcription regulation. A bi-functional DNA binding
protein BirA was responsible for this function (Streaker and Beckett, 1999). BirA was
both a negative regulator of the biotin biosynthetic operon and also served as a biotinactivating enzyme (Buoncristiani et al, 1986; Rodionov et al, 2002). Separate domains
were found to confer each function (Brennan et al, 1989). The C. trachomatis genome
was missing key biotin biosynthesis pathway genes. Moreover, the DNA binding domain
of the chlamydial birA gene was also missing. C. trachomatis expressed the bioY gene as
the only known uptake mechanism to obtain biotin. The presence of a regulated 5’UTR
might be a plausible alternative for the absence of a transcriptional regulator of biotin
uptake. Further experiments will shed more light on this potential riboswitch.
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CHAPTER 4. CHARACTERIZATION OF ncRNAs IN C. trachomatis D
4.1

MAPPING CHLAMYDIAL ncRNA

A subset of ncRNAs (10) that were detected during the discovery and validation
phase of the study were chosen for further analysis. They were compared to the
previously described CTIG675 (ihtA) and the pCHL1.2 plasmid antisense transcripts.
The selected ncRNAs included cis-acting ncRNAs (CTIG153, 270, and pCHL1.2),
potential trans-acting ncRNAs (CTIG241, 327, 356, 498, 504, 643, and 684), and a
potential riboswitch-like ncRNA (CTIG360).
We determined the 5’ and 3’ ends of each molecule using an RNA circularization
assay. The RNA circularization protocol was previously developed to assess the poly-A
status of RNAs (Urban and Vogel, 2008; Vogel and Hess, 2001). A schematic
representation of the procedure is shown in Figure 4-1.
Briefly, total RNA of a 24 h PI sample was treated with a tobacco acid
pyrophosphatase (to convert primary triphosphate to monophosphate groups), and
subjected to end circularization by T4 RNA ligase. Guided by the intergenic microarray
results we designed primers for cDNA synthesis of circularized RNA (Table 2-1 for list
of primers used, locate circularization primers under 5’3’ SEQ). After cDNA synthesis,
junction fragments were amplified by PCR (Figure 4-1), cloned, and sequenced (10 or
more clones per reaction). This analysis revealed the transcription start sites (TSS in
Table 4-1) for all 12 ncRNAs, including those with more than one species (CTIG643.1/2
and pCHL1.1/2, each pair had the same 5’ end but different 3’ ends). The smaller
fragment of CTIG153 could not be determined due to the constraints on primer design
presented by the small size of transcript and extensive secondary structures. The TSSs
determined by the RNA circularization procedure were used to predict potential
promoters for the ncRNAs (Table 4-1). The promoters identified were all of the σ66
family (the major sigma factor in C. trachomatis) but functional characterization of the
promoters was not performed and these remain predicted promoter elements at this point.

Figure 4-1 A schematic representation of the RNA circularization procedure. The
procedure begins with the removal of the 5’ pyrophosphate using tobacco acid
pyrophosphatase (TAP) followed by circularization using T4 RNA ligase. Primers were
then designed to amplify the 5’/3’ junction.
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Table 4-1 The 5’ and 3’ ends of the ncRNAs determined in this study.
3’end

Size

CTIG153

Promoter elements (P)
Arm
TSS
-35
-10
TTTACA TGTGATAGC N7 TGTAGA

TTCAGC*

159

CTIG241

TTTTCA

TATATT

N6

GGTTTA

TGCTTT*

80

CTIG270

TTTACT

TCTTAT

N9

AAATGT

TCTAAT*

222

CTIG327

TTGACA

GATTAT

N8

TTTAAG

TTTTAG*

308

CTIG356

TTTTTG

TATAAC

N12

AAAGTG

GTAGTG

209

CTIG360

ATGCAT

TAGACT

N6

AGTTTT

TCATAA

241

CTIG498

TTGTGG

TCCATT

N3

TCTGTA

GTAACT

111

CTIG504

TTGCTT

TACAAT

N6

TAGCTT

GTCGTT*

73

TTGACA

TATCAT

N5

CCCGGG

CGCAGT*

126

GCACCT*

331

CTIG675

TGGAAA

TGTTATAAG

N6

AAGTTG

TGGCTT*

106

CTIG684

TTGTAG

TACGAT

N6

CCAACA

CTGTCT*

83

TTGCCA

TATATT

N5

CATCTT

CCCCAC*

223

GCAAAC*

507

Name

CTIG643.1
CTIG643.2

pCHL1.1
pCHL1.2

The 5’ end is designated the TSS, the 3’ end and overall size of the ncRNAs is listed.
Non-coding RNAs that contained non-templated additions at the 3’ end are indicated by
an asterisk. Promoter predictions were made by examination of the areas immediately
upstream of the TSS. All of the predicted promoters were of the σ66 type and two had an
extended -10 sequence.
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Two of the ncRNA promoters have sequences characterized as encoding “extended” -10
regions. All promoters had acceptable -35 sequences that ranged from 6 out of 6 matches
to the -35 consensus [TTGACA] (CTIG327, and CTIG643), to 3 out of 6 match to
consensus (CTIG360, CTIG498, CTIG504, and CTIG684). Moreover all potential
promoters had acceptable -10 elements except for 2 cases, they ranged from 5 out of 6
ncRNAs had poor-10 elements, the match was only 2 out of 6 (CTIG327 and CTIG360).
match to the -10 consensus [TATAAT] (CTIG365, CTIG504, CTIG643, CTIG675, and
CHL1), to 3 out of 6 match to consensus (CTIG153, and CTIG498). Collectively the
combination of -10 and -35 promoter elements showed acceptable promoter strength.
Two promoters were questionable as to whether they represent true promoters. These
were CTIG360 and CTIG498; both had either 3 or 2 matches to the consensus in both the
-10 and -35 elements. These questionable promoter elements suggested that either these
two ncRNAs were not the primary transcript or that they represent an unusual chlamydial
promoter that might require chlamydial RNAP holoenzyme and/or transcription factors to
be recognized.
The spacer between the -10 element and the TSS is ideally 5 to 9 nucleotides
(Figure 1-2). 10 ncRNAs fall within this range and two were out of that range. For
CTIG356, the -10 element was located 12 nucleotides upstream of the TSS. The
promoter elements for CTIG356 were strong (5 out of 6 matches to the consensus in both
its -10 and -35 elements). The 12 nucleotide distance between the TSS and the -10
element can be interpreted as a post transcriptional processing from a longer RNA and
the native TSS might be 3 to 7 nucleotides upstream. CTIG498 had a short spacer arm of
3 nucleotides between the -10 element and the TSS. Combining this observation with its
two moderate to weak promoter elements (3 out of 6 match to the consensus), and that
the transcript is located at the 3’end of CT497 suggests that CTIG498 might not be a
primary transcript. CTIG498 might be a processed transcript from the CT497 mRNA.
Two promoters had extended -10 elements, namely CTIG153 and CTIG675
(ihtA). The predicted promoter for ihtA differed from the previously published promoter
(Grieshaber et al, 2006).
4.1.1

VERIFICATION OF TSS BY 5’RACE

We selected 7 ncRNA to verify their TSS using 5’RACE; namely CTIG153,
CTIG241, CTIG270, CTIG327, CTIG360, CTIG675, and CTIG684. Primers used for
these studies are listed in Table 2-1 under 5’RACE. RACE can be carried out in several
ways. All depend on the addition of a known sequence to the 5’ end of RNA (Adaptor
ligation) or to the 3’end of the generated cDNA (template switching reverse
transcriptase). We used template switching reverse transcriptase. It was a special RT
enzyme in that, upon reaching the 5’end of the mRNA, it acquired a terminal transferase
activity and added three Cs to the end of the newly formed cDNA. The newly added Cs
formed a sticky end that allowed the end to base-pair with 3 Gs. The sticky end base
paired with an adapter in the reaction mixture that had 3 Gs. The RT switched templates
and resumed its RT activity using the adapter as its new template. The result was a
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cDNA that had the complementary adapter sequence on its 3’ end (5’ end of the RNA).
cDNA was amplified by PCR (gene specific primer and Universal adapter primer). The
template switching technique was especially beneficial as it solved one of the problems
associated with TSS analysis. RNA tended to acquire different secondary structures that
required high temperatures to denature. The elevated temperatures were inhibitory to the
RT enzyme. In the template switching technique the presence of secondary structure led
to stalling of the RT, hindering the template switching and inhibiting amplification.
When the RT enzyme reached a true 5’ end of an RNA (be it a TSS or processed product)
it acquired a terminal transferase activity and template switching took place. This
technique selectively enriched for the full length cDNA rather than truncated products
due to secondary structures. 24h PI RNA samples were DNased twice (TurboDNase,
Ambion). cDNA was synthesized according to manufacturers instructions (Super
SMARTTM PCR cDNA synthesis, Clontech) using gene specific primers. The 3’ end of
cDNA was amplified, gel purified, cloned, and sequenced. Results confirmed the same
TSS determined by RNA circularization (Table 4-1).
4.1.2

IhtA PROMOTER ANALYSIS

Grieshaber et al, 2006 determined the TSS for ihtA using a primer extension
procedure. They determined the TSS to be 8 nucleotides downstream of the CT674 stop
codon. Surprisingly, when the TSS was determined using the RNA circularization
protoccol it was determined to be 16 nucleotides downstream of the CT674 stop codon
(Figure 4-2B). Based on the differences in TSS, two different promoter elements were
predicted. To address this discrepancy several experiments were carried out. First we
determined the TSS using 5’ RACE and the results confirmed the TSS of ihtA in Table
4-1 determined by RNA circularization. 2 clones for ihtA were constructed. ihtA was
cloned under its own promoter (E/C in Figure 4-2A) in a promoterless vector pSMARTHCAmp (CloneSmart® Blunt Cloning, Lucigen). ihtA was also cloned under a
tetracycline promoter such that its TSS would match the published TSS (E/T in Figure
4-2A) (for primers used see Table 2-1). Both clones were transformed into E. coli and
allowed to grow to OD600 of 1. RNA was harvested (MASTERPURE, Epicentre) from
both cultures and resolved on 10% UREA PAGE gels along with 40h PI chlamydial
RNA. RNA was then electrotransferred onto nylon membranes. The blot was probed
with an ihtA specific probe. Analyses indicated that both chlamydial RNA and E. coli
RNA (E/C) contained the same size band of about 100 bases. The clone E/T showed a
band migrating at a slightly larger size. The Northern blot showed that ihtA could be
transcribed from its own chlamydial promoter in E. coli. The blot suggests that ihtA with
the previously published TSS produced a larger product than native ihtA. In order to rule
out the size difference between C, E/C, and E/T were due to differences in the 3’ ends of
the RNAs we carried out RNA circularization for both clones E/C and E/T. The results
verified that the 5’ end of ihtA in E/C was identical to the chlamydial ihtA. The results
also verified that ihtA 5’ end in E/T clone was identical to the published TSS. Finally the
results confirmed that the 3’ ends of all clones were identical, and the only difference
between E/C and E/T was the difference in the predicted TSS.
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Figure 4-2 Resolving the ihtA promoter discrepancy. Panel A shows Northern blotting
results. Lane C represents chlamydial RNA, lane E/C represents RNA from E. coli
expressing ihtA from its native promoter, and lane E/T represents RNA from E. coli
expressing ihtA from a tetracycline promoter such that the TSS matches the published
TSS. Panel B represent a schematic of both promoter elements in which the red letters
represent published promoter elements and the underlined letters represent the promoter
as determined in this work. (Pub: published, TSS: transcription start site).
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4.1.3

NON-TEMPLATED ADDITIONS TO ncRNAs

During mapping of the chlamydial ncRNAs, the 3’ end of each transcript was
determined. The 3’ ends marked with an asterisk in Table 4-1 were determined to have
non-templated additions of variable sizes. Table 4-2 shows a summary of the nontemplated additions to ncRNAs’ 3’ends. For simplification, the table only includes
individual sequences that were composed of at least 4 nucleotides detected at the 3’ end
of RNAs. Generally, specific transcripts had between 3-5 added nucleotides (nt) but the
largest found was 27 nt. Although the additions were predominantly poly-A, several
non-templated additions contained G residues. Upon calculating the actual percentage of
each nucleotide in the non-templated additions we found that A represented 74%,
followed by G (16%), then T (8.2%) and finally C (1.7%).
We asked whether similar additions are present at the 3’ ends of mRNAs
encoding ORFs. We preformed RNA circularization assay for 5 chlamydial genes (i.e.
CT500, CT789, CT353, CT046, and CT099). We were able to identify the TSS for each
mRNA but none of these mRNA had non-templated additions at their 3’ ends.
4.2

DEVELOPMENTAL EXPRESSION OF ncRNA IN CHLAMYDIA

To determine the expression patterns of ncRNAs, we chose to examine i) their
expression during the normal developmental cycle, ii) their expression during IFN-γinduced persistence and reactivation, and iii) their expression during carbenicillininduced persistence and reactivation. DNA/RNA samples for the developmental cycle
were taken at 0, 3, 8, 16, 24 and 48 h PI as described previously (Belland et al, 2003b)
and shown in Figure 4-3. DNA/RNA was collected from IFN-γ-induced persistent
samples at 24, 48, 72 h PI and 12, 24, 48, 72 h post reactivation (IFN and IFN R in Figure
4-3). IFN-γ was used to induce persistence (5ng/ml, as determined by a pilot titration
experiment) and was added to the media 24 h prior to infection. Samples were
reactivated at 24 h PI by changing media with IFN-γ-free media containing excess
tryptophan (Belland et al, 2003a) and samples were taken at the times shown in Figure
4-3 (IFN and IFN R). Carbenicillin-induced persistence was induced by the addition of
the antibiotic (2g/ml, as determined by a pilot titration experiment) at the time of
infection. DNA/RNA was collected from carbenicillin-treated samples at 24, 48 h PI and
24, 48, and 72 h post reactivation (Cb and Cb R in Figure 4-3). As shown in Figure 4-4,
IFN- treatment resulted in a reduction of IFUs of ca. four logs at 48 h PI. Following
reactivation for 48 h, the IFU values returned to ca. 98% of control cultures, indicating
that RBs were present but were in a non-dividing or persistent state. Similarly,
carbenicillin treatment resulted in a distinct decrease in IFUs at 48 h PI, but following
removal of the antibiotic (Cb reactivation), IFU numbers returned to control levels
(Figure 4-4). Genome copy numbers for each of the samples was determined by qPCR as
previously described (Ouellette et al, 2006) and the samples were thoroughly DNased and
RNA was then re-purified. Expression of ncRNAs was determined by Northern blotting
of RNA samples from equivalent numbers of bacteria (as determined by genomic
normalization) for the developmental cycle and carbenicillin persistence. Samples used
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Table 4-2 Non-templated additions to chlamydial ncRNAs 3' ends.
Sequence
AGAGAAA
AAAAGTA
AAAGTG
AAGA
AAAAAAA
CTIG153
AAAAAAA
AAAAA
AAAAA
AAAA
AAAA
AAGAAATAAGAGAAGAG
AGAAAATGAGAAAG
CTIG241 AGGGAGAAGAAAG
AAAAAAGGAAG
AAAAA
AAAAAAA
CTIG270
AAAAAA
GGGAGTGGAAG
CTIG327 ATTTT
TTTT
CTIG643-2 AAAAAAGC
GTAAAAAAAAAAACAACAAGAGACAAG
AAATAAAAG
GAAAGAGA
AAAAAAA
CTIG675 AAAAAAA
AAAAAAA
AAAAAAA
AAAA
AAAA
pCHL1.1 AAGGAGCAAAAAAAA
Name
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Figure 4-3 Scheme of nucleic acid sample collection during chlamydial developmental
cycle, IFN-γ-induced and carbenicillin-induced persistence and reactivation. IFN: IFN-γ
Persistence, Cb: Carbenicillin Persistence, R: Reactivation.
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Figure 4-4 Titration results and establishment of persistence and reactivation. IFN: IFNγ persistence, Cb: carbenicillin persistence, R: reactivation, IFU infectious units.
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for IFN-γ persistence contained 20% of the genome numbers used for the other analyses
due to the reduced chlamydial biomass associated with growth in the presence of IFN-γ.
We chose to group results by ncRNAs rather than by condition, where all blots for each
ncRNA are grouped in a single panel to allow for direct comparisons between normal and
persistent growth conditions. The results in Figure 4-5 show ncRNA expression patterns
for genes that predominantly express a single transcript while those in Figure 4-6 show
the results for ncRNAs that are expressed as multiple species (both figures also show the
genomic-locus of each ncRNA).
4.2.1

DEVELOPMENTAL CYCLE

Expression during the normal developmental cycle showed differences between
the ncRNAs examined in the onset and point of maximal expression of different
transcripts, indicating that ncRNA transcription is both tightly and temporally regulated.
Four ncRNAs showed onset of expression at ca. 8 h PI i.e. CTIG153.1/.2 (Figure 4-6A),
CTIG356 (Figure 4-5D), CTIG360 (Figure 4-5E), and the plasmid antisense transcripts
pCHL1.1/.2. Seven ncRNAs were first expressed at ca. 16 h PI i.e. CTIG241 (Figure
4-5A), CTIG327 (Figure 4-5C), CTIG498 (Figure 4-5F), CTIG504 (Figure 4-5G),
CTIG643.1/.2 (Figure 4-6B), CTIG675/IhtA (Figure 4-5H), and CTIG684 (Figure 4-6C).
The cis-acting CTIG270, that overlaps the ftsI gene, was the only ncRNA that was
expressed late in the cycle at ca. 24 h PI.
4.2.2

IFN-γ-INDUCED PERSISTENCE

Six ncRNAs (CTIG270, CTIG327, CTIG360, CTIG498, CTIG643.1/.2), and
CTIG684) were not detectable during IFN-γ persistence. CTIG360 (Figure 4-5E)
resumed expression as early as 12 h after reactivation and its expression peaked at 24h
post-reactivation. CTIG270 (Figure 4-5B), CTIG327 (Figure 4-5C) and CTIG684 (Figure
4-6C) were expressed at a much reduced intensity during the first 24 h post-reactivation
and were undetectable at later time points while CTIG498 (Figure 4-5F) and CTIG643
(Figure 4-6B) did not appear to be expressed during reactivation.
Six ncRNAs (CTIG153.1/.2, CTIG241, CTIG356, CTIG504, CTIG675, and
pCHL1.1& (.2)) were expressed to some degree during IFN-γ persistence. CTIG153.2
short-form (Figure 4-6A) was expressed at a high level during IFN-γ persistence, while
expression of the longer form (CTIG153.1) declined rapidly. During reactivation, both
forms declined at approximately the same rate and by 48 h PR they were no longer
detectable. CTIG241 (Figure 4-5A), CTIG356 (Figure 4-5D), CTIG675 (Figure 4-5H),
and the plasmid antisense pCHL.1/.2 (Figure 4-6D) were expressed at low levels during
IFN-γ persistence but showed increased expression levels following reactivation.
CTIG504 (Figure 4-5G) was expressed at ca. the same level throughout IFN-γ-induced
persistence and reactivation.
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Figure 4-5 Developmental expression of ncRNAs in C. trachomatis during the
developmental cycle, IFN-γ-induced and carbenicillin-induced persistence and
reactivation. Each panel (A-H) shows the expression pattern of the particular ncRNA
under the conditions described in Figure 4-3. In addition the genomic position of
ncRNAs is shown in the schematic panel; black arrowheads represent ncRNAs, while
gray arrowheads represent tRNA.
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Figure 4-6 Developmental expression of the processed forms of ncRNAs in C.
trachomatis during the developmental cycle, IFN-γ-induced and carbenicillin-induced
persistence and reactivation. Each panel (A-D) shows the expression pattern of the
particular ncRNA under the conditions described in Figure 4-3. In addition the genomic
position and orientation of the ncRNAs are shown in the schematic panel under the
developmental cycle panel.
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4.2.3

CARBENICILLIN-INDUCED PERSISTENCE

In contrast to the situation with IFN-γ-induced persistence, virtually all tested
ncRNAs showed significant expression during carbenicillin treatment. The exception
was CTIG270 (Figure 4-5B), which was undetectable during carbenicillin treatment and
was transiently expressed 24 h after reactivation.
Nine ncRNAs (CTIG153.1/.2), CTIG327, CTIG356, CTIG360, CTIG498,
CTIG643.1, CTIG675, CTIG684, and pCHL1.1) showed a decline in expression as the
infection progressed from 24 h PI to 48 h PI. This decline in expression ranged from a
slight reduction to complete disappearance of the transcripts, as evident with CTIG498
(Figure 4-5F), CTIG684 (Figure 4-6C), and pCHL1.1 (the longer plasmid antisense
transcript, Figure 4-6D). In contrast, the only ncRNA to show a marked increase in
transcript levels during carbenicillin treatment was CTIG643.2 (the longer transcript,
Figure 4-6B). Two ncRNAs showed little change in transcript levels during persistence
(CTIG241; Figure 4-5A, and pCHL1.2; Figure 4-6D). Transcript levels for virtually all
of the tested ncRNA were detectable 24h post-reactivation. Many of these declined to
the point at which they could not be detected at 48h post-reactivation (CTIG153.1& (.2),
CTIG270, CTIG327, CTIG360, CTIG684, and pCHL1.1) while the rest declined to some
degree as the reactivation progressed from 24 to 72 hours. CTIG498 (Figure 4-5F) was
the exception at it was not detected during the course of reactivation from carbenicillin
treatment.
4.3
4.3.1

DISCUSSION

RNA CIRCULARIZATION TECHNIQUE

We used an RNA circularization technique for mapping ncRNAs. The technique
offered a reliable and cost effective method that determines both the 5’ and 3’ ends of
RNA. Moreover, this technique was successful at identifying 3’ non templated additions.
RNA circularization was used to identify the ends of 11 mRNAs and rRNAs of the
mitochondrial genome of Drosophila melanogaster (Stewart and Beckenbach, 2009). It
was also applied in a protocol termed “ligation-mediated PCR” allowing the detection
and mapping of cleavage products of specific nucleic acid molecules out of complex
nucleic acid mixtures (Grange, 2008). Moreover, the RNA circularization technique was
also used to monitor the editing processes that result in the structural retailoring of the
aminoacyl acceptor stems of mitochondrial tRNAs (Lohan and Gray, 2007). From these
examples and others, it is clear that RNA circularization is a reliable technique for
mapping RNA ends.
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4.3.2

POTENTIAL PROMOTER ELEMENTS FOR ncRNAs

In E. coli the consensus arrangement for the major sigma factor is shown in
Figure 1-2 (reviewed in Ross and Gourse, 2009). Although there appear to be
considerable levels of homology between C. trachomatis σ66 and E. coli σ70, Mathews
and Sriprakash reported that chlamydial RNA polymerase can tolerate considerably more
variation at the -10 and -35 regions (Mathews and Sriprakash, 1994). In general, most
published σ66 promoter elements have acceptable variation from the consensus (Engel and
Ganem, 1987; Birkelund et al, 1989; Douglas and Hatch, 1995, 1996; Ochiai et al, 1999;
Shen et al, 2000; Schaumburg and Tan, 2003; Grech et al, 2007). Therefore; except for
CTIG360 and CTIG498, the predicted promoters are σ66 promoters.
Two of the predicted promoters had extended -10 characteristics. Extended –10
promoter elements are present in ~20% of all E. coli genes (Burr et al, 2000). The
primary σ factor (σ70) has four regions of similarity. It is known that residues in region 2
recognize a −10 element (TATAAT) (Murakami et al, 2002), residues in region 3
recognize an extended TGn −10 element (positions −15 to −13) (Barne et al, 1997), and
residues in region 4 recognize a −35 element (TTGACA) (Campbell et al, 2002).
However, not all three of these promoter elements need to be present for promoter
function. E. coli σ70-dependent promoters have typically been characterized as either
−10/−35 promoters, which have good matches to both the canonical −10 and −35
sequences and do not require the TGn motif (McClure et al, 1983), or as extended -10
promoters (TGn/-10 promoters) which have the TGn motif and an excellent match to the
-10 consensus sequence and do not require a -35 element (Kumar et al, 1993; Lisser and
Margalit, 1993; Browning and Busby, 2004). In E. coli, extended -10 promoters have
several characteristics, Extended -10 promoters, tend to have longer spacer (distance
between -10and -35 elements) lengths than promoters that do not. They also tend to show
fewer matches to the canonical -35 elements (Mitchell et al, 2003). More importantly
open promoter complexes can be formed on an extended -10 promoter at temperatures as
low as 6°C a temperature at which complexes on most promoters are closed (Minakhin
and Severinov, 2003).
The TSSs in Table 4-1 predict 2 potential extended -10 promoters, CTIG153 and
ihtA. Similar to σ70 in E. coli, chlamydial σ66 needs only regions 2 and 3 to interact with
extended -10 promoters. A large and diverse family of proteins known as “anti-σ factors”
regulates utilization of particular classes of bacterial promoters by targeting specific σ
factors (Helmann, 1999; Hughes and Mathee, 1998). Typically, anti-σ factors interact
with core binding determinants in their cognate σ factors, thereby preventing their
association with the RNAP core enzyme (Campbell et al, 2008). The AsiA protein of
bacteriophage T4 is one of the earliest anti-σ factors to be identified. It targets σ70 (Orsini
et al, 1993; Severinova et al, 1996), however, unlike most other well-characterized anti-σ
factors, AsiA binds to σ70 primarily through an interaction with σ70 conserved region 4.2
which has also been implicated in sequence-specific recognition of the -35 consensus
promoter element (Severinova et al, 1998; Yuan et al, 2009). As a component of the σ70containing holoenzyme, AsiA inhibits transcription from the -10/-35 class of promoters,
but does not inhibit transcription from extended-10 promoters (Severinova et al, 1998).
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Interestingly, CT663 interacts with the flap domain of the β subunit (beta-flap) of RNA
polymerase core enzyme, and the conserved region 4 of the primary sigma subunit σ66 in
C. trachomatis. CT663 inhibits σ66-dependent transcription in vitro (Rao et al, 2009).
Thus there is a possibility that CT663 may have a role in regulating transcription of TGn
and nonTGn promoters.
4.3.3

NON-TEMPLATED ADDITIONS ON THE 3’ENDS OF ncRNA

It has been shown that prokaryotes posses two enzymes that can add nucleotides
to the 3’ ends of RNA without a template, namely Poly(A) polymerase I (PAPI) (Paschal
et al, 2008) and Polynucleotide phosphorylase (PNPase) (Grunberg-Manago et al, 1955).
Both enzymes are involved in modulating RNA stability (Carpousis et al, 1999);
(Carpousis et al, 2008). PAPI, adds poly(A) extensions to the 3′ ends of mRNAs, as well
as to tRNA and rRNA (Li et al, 1998). PNPase on the other hand, adds long,
heteropolymeric tails in vivo (Mohanty and Kushner, 2000). Polyadenylation of RNAs
by PAPI in E. coli plays a significant role in mRNA decay and general RNA quality
control (Jasiecki and Wegrzyn, 2003; Mohanty and Kushner, 2006). Chlamydial
genomes contain 2 paralogues of PAPI (CT410 and CT704) and one PNPase (CT842).
We believe that the observed non-templated tails are due to the activities of these
enzymes. The tails composed of only As are probably due to the activity of PAPI, while
the heteropolymeric tails are probably due to the activity of PNPase. In either case the
modified RNA represent an intermediate for degradation. The heteropolymeric tails in
Chlamydia were shown to contain the different nucleotides according to the following
preference A > G > U > C. The same preference was also observed for E. coli PNPase
(Mohanty et al, 2000).
Regulation of ncRNAs by polyadenylation was well characterized in the
glmS/glmZ/glmY system (Kalamorz et al, 2007; Reichenbach et al, 2008). Translation of
the glmS mRNA was normally weak since an internal hairpin structure containing the
glmS Shine Dalgarno sequence limits ribosome access to the downstream glmS RBS and
therefore GlmS synthesis (Kalamorz et al, 2007; Urban et al, 2008). glmZ, an ncRNA,
functions as an anti-antisense and melts this hairpin, allowing glmS translation. glmZ is
unstable and its stability is greatly increases by glmY, another ncRNA. Thus the levels of
GlmS are affected by glmZ, which in turn is affected by glmY (Kalamorz et al, 2007).
glmY levels are controlled by polyadenylation and it was found that about 50% of glmY is
polyadenylated. This regulatory hierarchy signifies the effect of polyadenylation on the
function of glmS/glmZ/glmY (Urban et al, 2008) reviewed in (Gorke and Vogel, 2008).
4.3.4

ncRNA EXPRESSION UNDER BOTH NORMAL AND STRESS
CONDITIONS

The ncRNAs shown in this study may represent a subset of the total C.
trachomatis ncRNAs since initial identifications were done using RNA from late stage
infection (40h PI). For example, ncRNAs that were only expressed during the early
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stages of the developmental cycle were not tested. The technical difficulties associated
with obtaining sufficient RNA from early stages of the developmental cycle have
hindered this approach. Most of the ncRNAs showed a decrease in expression during the
late stages of the developmental cycle, a point in which the predominant developmental
forms are the infectious, non-metabolizing EBs.
As is the case with many ncRNAs, their expression is tightly controlled. Their
might be a significant portion of chlamydial ncRNAs that are not induced under normal
developmental conditions but could be induced under various stress conditions. Thus it
may be worthwhile to catalogue stress-induced ncRNAs, after establishing the
appropriate system to screen their functions.
The predicted target of CTIG270 is the ftsI transcript encoding FtsI. FtsI in other
bacteria is associated with peptidoglycan modification during cell division. CTIG270
was the only ncRNA to show late onset of transcription (24h PI). At this time chlamydial
inclusions are easily visible under the microscope and some EBs can be seen inside
inclusions. This timing of expression reinforces the hypothesis that this RNA controls
ftsI mRNA, as one of the hallmarks of RB to EB differentiation is the inhibition of cell
division. For further discussion concerning CTIG270 and ftsI, please refer to section
5.2.1 below.
One of the interesting ncRNAs was CTIG643.1&.2 (long and short transcript
respectively) as there is a significant difference in expression between the normal
developmental cycle and carbenicillin treatment. The sequence of CTIG643.2 shows a
rho independent terminator marking its 3’ end. During the developmental cycle the rho
independent terminator was not functional and the major transcript detected was the
longer transcript (CTIG643.1). During carbenicillin treatment, RNA polymerase
terminated efficiently at the rho independent terminator producing primarily CTIG643.2.
This interesting phenomenon can be interpreted in two ways. Either the RNA
polymerase enzyme became increasingly sensitive to termination during carbenicillin
treatment or there is a factor that bound the RNAP and prevented its termination during
the normal developmental cycle. This factor might be unavailable during persistence.
The C. trachomatis genome encodes three factors involved in termination/antitermination; NusA (CT097), NusG (CT320), and GreA (CT636). NusA is an essential
multifunctional transcription elongation factor that is universally conserved among
eubacteria and archaea (Nudler and Gottesman, 2002). NusA may elicit opposite effects
on transcription (Richardson, 1996). By itself, NusA stimulates pausing at some hairpins
and rho-independent terminators. In complex with other Nus factors (e.g. NusG) it
stimulates anti-termination at both rho-dependent and rho-independent terminators
(Richardson, 1996; Nudler et al, 2002). GreA, functions when transcription elongation
slows or stops completely at certain points of the template, resulting in formation of
paused or arrested complexes. In these complexes, RNAP shifts along the DNA template
in the direction opposite to that of transcription (Komissarova and Kashlev, 1997; Nudler
et al, 1997). As a result, the 3' end of RNA disengages from the RNAP catalytic center
making further elongation impossible. An arrested complex can resume transcript
elongation only following endonucleolytic cleavage of the nascent RNA that generates a
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new 3' end of the transcript in the RNAP catalytic center. The endonucleolytic reaction
performed by the RNAP catalytic center is slow, but is greatly stimulated by transcript
cleavage factors including GreA (Fish and Kane, 2002; Sergei et al, 2005; Stepanova et
al, 2007). A recent study of iron induced persistence in C. trachomatis E showed that
both NusA and NusG were regulated (Dill et al, 2009). This study is intriguing as it
shows that Nus factors are regulated during persistence and might explain why CTIG643
shows such discrepancy in termination under normal and stress conditions.
CTIG360 was described earlier as a potential riboswitch for the bioY gene.
CTIG360 was expressed early during the normal developmental cycle and was also
detected during carbenicillin treatment. It was not detected during IFN-γ-induced
persistence but its expression was readily detected during reactivation. IFN-γ induced
persistence analyses indicated that, although CTIG360 was not detected, a larger product
(> 500 nt) was detected. The bioY gene is ca. 785 bp, including its 5’UTR. There is a
possibility that this band represented the full length bioY mRNA. Chlamydia is a biotin
auxotroph and might be sensing a need to transport biotin under IFN-γ treatment, thus
allowing for more full length transporter gene to be transcribed. Under normal growth
conditions there may be enough biotin that the transporter is down-regulated. This
hypothesis needs more testing to verify such claims. We are currently undergoing
detailed experiments using E. coli lacking bioY function to verify the function of the
chlamydial bioY ortholog and to test the riboswitch hypothesis.
4.3.5

SIGNIFICANCE OF MULTIBLE BANDS FOR A SINGLE ncRNA

The expression of multiple species of ncRNAs has been previously described (e.g.
for gadY, (Opdyke et al, 2004), dsrA (Repoila and Gottesman, 2001), and glmY
(Reichenbach et al, 2008)) and is believed to involve post-transcriptional processing that
is dependent on the balance between protection by RNA binding protein(s) and
degradation by RNases. The functional significance has not been well-studied but,
importantly, Davis and Waldor (Davis and Waldor, 2007) have shown that MicX of
Vibrio cholerae can be detected as both an active precursor and a processed form and that
the smaller, processed molecule is significantly more stable and abundant. Interestingly,
processing occurs in an Hfq and RNase E-dependent manner but the regulatory effects of
MicX on its target mRNA is not dependent on Hfq. Chlamydia spp. do not contain
obvious orthologs of Hfq or RNase E, suggesting that regulation and processing may be
very different in these organisms.
The presence of several bands representing a single ncRNA occurs because the
ncRNA is processed (CTIG153, pCHL1) or the ncRNA might incompletely terminate at a
rho independent terminator (CTIG643). The relative abundance of each band on the
Northern blotting followed two different kinetic profiles (Figure 4-6). One profile shows
identical relative intensities of both bands representing a single ncRNA. This group is
represented by (CTIG153, pCHL1, CTIG643, and CTIG684) under normal developmental
condition. The second profile shows different relative intensities, e.g. under carbenicillin
treatment the small band was dominant for CTIG153, CTIG643 and pCHL1. Previous
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discussion of CTIG643 indicated a likely mechanism, but for CTIG153 and pCHL1 there
is no terminator in either RNA. Multiple bands in CTIG153 and pCHL1 might be due to
processing of the 3’ end as both ncRNAs are antisense transcripts and the short
transcripts represent the 5’ half of the molecule. Apparently the 3’ end of the molecule
was cleaved after forming double stranded RNA with the target gene. Processing of
double stranded RNA may be carried out by chlamydial RNase III (CT297) and/or RNase
G (CT808).
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CHAPTER 5. FUNCTIONAL ANALYSIS OF ncRNA
5.1
5.1.1

CIS-ACTING CTIG270

VERIFICATION OF CTIG270 MAPPING

One of the cis-acting ncRNAs (CTIG270) (Figure 3-1) was selected for further
analysis. Mapping of CTIG270 transcript was carried out using the RNA circularization
protocol (Table 4-1). CTIG270 extends on the upper strand 142 and 80 nucleotides 5’
and 3’ to the ftsI stop codon respectively (Table 4-1). Mapping was verified using 5’
RACE using C. trachomatis RNA from 24h PI (Super SMARTTM PCR cDNA synthesis,
Clontech). The amplified 5’RACE product was TA cloned into pCR2.1 (Invitrogen, CA)
and individual clones sequenced. Results identified a TSS for CTIG270 similar to what
was reported in (Table 4-1).
5.1.2

FUNCTIONAL ANALYSIS OF CTIG270 IN A SURROGATE SYSTEM

To test the effect of expression of CTIG270 on ftsI, a system was constructed
where both ftsI and CTIG270 were cloned in two compatible medium copy number
plasmids and transformed into E. coli. ftsI was fused in frame to a 5’ FLAG-tag sequence
(N-DYKDDDDK-C) and cloned under the control of a lac promoter (from pCR2.1,
Invitrogen).
When CTIG270 was induced (Figure 5-1 lane 1 panel C) neither the FLAG-ftsI
protein nor its mRNA were detected (Figure 5-1 lane 1 panel A, B). When the second
inducer was added (Figure 5-1 lanes 2 and 3), the FLAG-ftsI protein and its mRNA were
undetectable. The amount of CTIG270 detected was reduced by the end of the double
induction period and none of the RNAs or protein was detectable (Figure 5-1 lane 3).
When the expression of the FLAG-tagged ftsI was induced by IPTG; both the
mRNA and protein were detectable (Figure 5-1 lane 4). When the second inducer was
added (Arabinose) CTIG270 was detected and both FLAG-ftsI protein and its mRNA
were transiently increased (Figure 5-1 lane 5). By the end of the double induction period,
the FLAG-ftsI protein and its mRNA were barely detectable, and CTIG270 was markedly
reduced (Figure 5-1 lane 6).
The control culture (no induction) showed little to no expression (Figure 5-1 lane
7). When both inducers were added both RNAs and the protein were detected (Figure
5-1 lane 8). By the end of the co-induction experiment the FLAG-ftsI protein and its
mRNA were not detectable and reduced amounts of CTIG270 were detectable.
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Figure 5-1 CTIG270 analysis in an E. coli surrogate system. Lanes 1, 2, 3 represent
induction by arabinose followed by IPTG, lanes 4, 5, 6 represent induction by IPTG
followed by arabinose, lane 7 represents no induction, lanes 8, 9 represent double
induction. Panel A showed Western blotting for a FLAG tagged ftsI, Panel B showed
Northern blotting for ftsI mRNA, Panel C showed Northern blotting for CTIG270. Ara:
arabinose.
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5.1.3

IN-VIVO EXPRESSION OF CTIG270 AND ftsI

We analyzed the expression of both CTIG270 and ftsI using matched Northern
blotting and reverse transcription-PCR respectively. The expression of ftsI mRNA
reached its maximum 16h PI. On the other hand, CTIG270 was barely detectable at the
same time point (Figure 5-2). By 24h PI, CTIG270 expression reached its maximum
while ftsI expression level was steadily decreasing. By 48h PI, both RNAs were barely
detectable.
5.2
5.2.1

DISCUSSION

USING E. coli AS A SURROGATE SYSTEM

We used an E. coli surrogate expression system because we lack an established
genetic system to manipulate Chlamydia. The results show possible mechanisms of
action that might take place in vivo during an actual infection. The results must be
understood in the contexts of an actual chlamydial infection (in a monolayer or in clinical
samples). Knowing that both E. coli and Chlamydia are different and knowing that E.
coli has the RNA chaperone Hfq, while Chlamydia lacks this protein, we examined the
results.
The matched RT-PCR/Northern results for ftsI/CTIG270 (Figure 5-2) show the
levels of both species of RNA in vivo. When the expression of ftsI was at its maximum
level, the expression of CTIG270 was undetectable. On the contrary, when the
expression of CTIG270 reached its maximum level ftsI mRNA level was rapidly
declining. This pattern is suggestive of an antisense regulation system, and it adds an
indirect in vivo validation for results obtained from the surrogate system.
It has been shown that Arabinose can act as an inducer for lac derived promoters
in E. coli (Narayanan et al, 2006). This is evident in Figure 5-1 lanes 5 which showed a
transient increase in the FLAG-FtsI protein and RNA under arabinose induction. This is
why we switched from using lac promoters to tetracycline promoters in later experiments
(described later).
5.2.2

EXPRESSION OF CTIG270 DURING STRESS CONDITIONS

The results of the surrogate expression system showed an efficient tight regulation
of the FLAG tagged ftsI. CTIG270 controlled the expression of its target gene whether it
was induced before or after target gene induction. In Figure 5-1 lanes 3, 6, and 9, both
inducers were present and both RNAs were transcribed. Interestingly we could not detect
either the FLAG-FtsI protein or its mRNA and very little CTIG270 was detected. This
result helped us to interpret the CTIG270 expression pattern during IFN-γ persistence
(Figure 4-5 panel B). The expression of CTIG270 was greatly reduced during IFN-γ
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Figure 5-2 RT-PCR of ftsI mRNA and CTIG270 Northern blotting during normal
developmental cycle. EB: elementary bodies (time zero).
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treatment. IFN-γ-induced persistence was associated with a block in RB cell division and
the presence of large, multinucleate RBs within the inclusion (Beatty et al, 1993). The
lack of CTIG270 signal during IFN-γ-induced persistence implied that either the ncRNA
was not transcribed or that the ncRNA is binding to its target and is being rapidly
degraded by RNase. The idea appears radical, but if the function of CTIG270 was to
quantitatively degrade its target mRNA then the lack of signal on the Northern blotting
might be because the ncRNA is highly active. CTIG270 may be playing a role in the lack
of bacterial cell division. C. trachomatis, although lacking Hfq and RNase E, encodes a
homolog of RNase III which, among other functions, can degrade dsRNA (Viegas et al,
2007). To test this phenomenon we may need to genetically control the expression of ftsI
inside Chlamydia and measure the effect on CTIG270 transcript half life at various time
points.
During carbenicillin treatment CTIG270 was not detected and treatment with
carbenicillin and other β-lactams results in very large, aberrant RBs that appear to have a
distinct block in cell division. However, in this case the situation is somewhat different
as FtsI (a penicillin binding protein) is also a target of carbenicillin. In other words, FtsI
is already under tight functional control from the antibiotic. In summary, the delayed
expression of CTIG270 and then the complete disappearance of the ncRNA during
persistence fits with our hypothesis that CTIG270 is regulating ftsI mRNA.
5.3

5.3.1

DESIGN AND OPTIMIZATION OF A SCREENING TOOL FOR transACTING ncRNA
RATIONAL

Screening the chlamydial genome for potential ncRNA targets was a novel goal.
We proposed several criteria for designing a screening system. These criteria were
pivotal so that the system would be functional and useful:
 Genomic DNA fragments will be cloned in a translational fusion with a reporter
system (target plasmid). Upon inhibition of translation a phenotype can be
visually detected.
 The phenotype elicited by translational inhibition of the reporter system should be
easily distinguished. This phenotype should allow selection of positive clones
from a larger number of negative background clones.
 During transformation, E. coli that takes up a self-ligated plasmid would not
survive phase I selection, thus reducing plasmid load.
 Target plasmid with library inserts that are out of frame with the reporter system
would not survive phase I selection. Phase I selection will reduce the genomic

71

fragments under test to include only genomic fragments in frame with the reporter
system.
 Target plasmid should be a low or medium copy plasmid.
 Plasmid carrying the ncRNA (effector plasmid) should be a high copy plasmid
compatible with the target plasmid.
 Expression of both the genomic DNA/reporter system and the ncRNA should be
controllable.
We designed a screening system that would fulfill these criteria. The system
underwent an optimization process until a target plasmid was constructed that adequately
fulfilled the aforementioned criteria.
We used the pZ modular plasmid system designed by Lutz and Bujard (Lutz and
Bujard, 1997). The pZ vector comprised of three main modules separated by unique
cleavage sites. The modular organization of the plasmid made it easy to exchange
promoters, origins of replication, and RBS. We used plasmid pZS*24MCS (Figure 5-3)
as the parent plasmid, this plasmid had origin of replication SC101* (3-5 plasmid copy
numbers/cell) (Manen et al, 1994) and had Kanamicin as a selectable marker. Module I
contained the promoter/operator construct, and ribosomal binding site (RBS). This
module was flanked by AatII/EcoRI. Module II harbored one of several compatible
origins of replication (ColE1, p15A, pSC101*). This module was flanked by AvrII/SacI.
Module III contained one of five antibiotic resistance markers for our purpose we used
Kanamicin resistance marker.
5.3.2

SCREENING SYSTEM DESIGN

Target plasmid: in order to construct the target plasmid, we used life/death as a
selection tool. Life/death selection was used for phase I selection which involved
elimination of non-translational fusions and self ligations. Life/death selection was also
used in phase II selection which involved selection of potential targets for ncRNA.
Life/death selection was established by using a fusion between a positive
selection gene and a negative selection gene. The positive selection gene was an
antibiotic marker, (chloramphenicol acetyltransferase (CAT)). The negative selection
gene was a toxic gene (ccdB). ccdB is a member of the ccd poison/antidote system of the
F plasmid (Critchlow et al, 1997; Maki et al, 1996). This system encodes a toxin
targeting the essential E. coli DNA gyrase. CcdB inhibits DNA gyrase leading to
unrepaired strand breaks and disintegration of the bacterial chromosome. CcdA, On the
other hand, is the antidote, it interacts with CcdB protein to neutralize its toxicity
(Bahassi et al, 1999). This toxin-antitoxin system was explored by other investigators
(Gabant et al, 1997), and ccdB gene is in use in the Invitrogen Gateway systemTM. The
reporter system was a translational fusion between ccdB and CAT (ccdB-CAT).
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Figure 5-3 Vector pZS*24MCS. The vector had Plac/ara promoter, flanked by
AatII/EcoRI, the map also shows pSC101* origin of replication flaked by AvrII/SacI.
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The fusion gene was under a PLtetO-1 promoter (Lutz et al, 1997). Figure 5-4
represents a schematic of the fusion gene. ccdB was cloned with no translational signal
(RBS and the first ATG) at the 5’ end. The absence of a translational signal upstream of
the fusion genes prevented the ribosomes from binding to the newly formed mRNA.
When the fusion gene was transcribed the cells maintained their sensitivity to
chloramphenicol. The fusion gene was constructed as follows: briefly ccdB and CAT
were amplified separately by PCR using the Gateway Vector Conversion System as a
template (Invitrogen, CA). Sequential PCR reactions were used to add the PLtetO-1
promoter sequence along with a StuI site directly upstream of ccdB second codon. PCR
was also used to create a 15-base overlap between ccdB 3’ end and the CAT 5’ end.
During primer design the first ATGs of both ccdB and CAT were eliminated along with
ccdB stop codon. The 15-base overlaps between ccdB and CAT were designed to keep
both genes in frame after recombination. PCR products were gel purified and
recombined using PCR InFusion Cloning kit (Clontech, CA) according to manufacturer’s
instructions. The recombination product was selected and amplified using appropriate
PCR primers. PCR was used to create 15 base overlaps between the fusion gene and the
linearized target plasmid. Plasmid pZS*24MCS was digested with AatII/EcoRI (NEB,
MA) to remove the promoter, RBS, and the multiple cloning site (MCS). The ccdB-CAT
fusion PCR amplicon was gel purified and recombined with the linearized pZS*24MCS
plasmid using PCR InFusion Cloning kit (Clontech, CA). The recombined plasmid was
transformed into electrocompetent One Shot ccdB Survival Cells (Invitrogen, CA). The
ccdB Survival cells were used because they were resistant to the cytotoxic effect of CcdB
protein. These cells had a mutation in the gyrA gene (Arg462/Cys substitution) (Bernard
and Couturier, 1992; Bernard et al, 1993). Transformants were selected on LB agar
Kanamicin plates (25µg/ml). For list of primers see Table 2-1 under ccdB/CAT Cloning.
The fusion gene lacked a translational start signal. For the fusion gene to be translated it
required an in frame translational signal supplied by the chlamydial genomic library. E.
coli where the fusion protein was produced were chloramphenicol resistant, while E. coli
where the fusion protein was not produced were chloramphenicol sensitive.
5.3.3

FUNCTIONAL TESTING OF THE TARGET PLASMID

Testing the target plasmid was carried out by supplying a translational signal to
ccdB-CAT fusion gene. This was followed by investigating whether the resulting plasmid
confers chloramphenicol resistance to ccdB resistant E. coli (positive selection) and
whether it subjects ccdB sensitive E. coli to ccdB mediated killing (negative selection).

Figure 5-4 Initial design of the fusion reporter system.
74

To carry out this test, target plasmid was linearized by StuI digestion (NEB, MA). The
translational signal was supplied by hctA leader/ATG. hctA leader sequence was
amplified by PCR and the amplicon included all the 5’UTR of hctA plus the first ATG
(Fahr et al, 1995) (Table 2-1 under Test SEQ Cloning). PCR was also used to add 15
base overlaps with both ends of the StuI linearized plasmid as shown in Figure 5-5. The
resulting plasmid was transformed into electrocompetent One Shot ccdB Survival Cells
and selected on Kanamicin (25µg/ml)/chloramphenicol (12.5µg/ml) LB Agar plates.
Clones were screened by PCR and confirmed by sequencing. ccdB Survival cells
containing translatable fusion gene were resistant to chloramphenicol. This implied that
the fusion gene was translated and cells acquired chloramphenicol resistance phenotype.
The Target plasmid containing translatable fusion gene was transformed into ccdB
sensitive cells (Bl21A1 E. coli, Invitrogen) and grown on Kanamicin/chloramphenicol
LB agar plates. Cells survived this selection. The lack of lethal effect of CcdB was not a
result of lack of translation of the fusion gene but rather CcdB in the fused form might
not be functional.
5.4

REDESIGN OF THE TARGET PLASMID

To address the loss of function of CcdB in the fusion form, we decided to insert
two protease cleavage sites flanking ccdB. Upon translation of the fusion gene, a
protease will regenerate the native CcdB.
Many proteases were used to cleave fusion proteins. For example, activated
blood coagulation factor X (factor Xa), enteropeptidase (enterokinase) and α-thrombin
have been used. There are many reports of fusion proteins that were cleaved by these

Figure 5-5 Schematic of the PCR infusion cloning.
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proteases at locations other than the designed site (Forsberg et al, 1992; Forsberg et al,
1991; He et al, 1993; Stevens, 2000; Wagner et al, 1996), We selected tobacco etch virus
protease (TEV protease) (Carrington and Dougherty, 1987, 1988) for use in the target
plasmid, as the TEV protease had higher stringent sequence specificity than many other
proteases (Dougherty et al, 1989; Kapust et al, 2002), it was already in use to cleave
fusion proteins in vivo (in E. coli) (Shih et al, 2005) and in vitro for affinity purification
(Babu et al, 2009; Song et al, 2009). TEV protease cleaves the amino acid sequence
ENLYFQG/S between QG or QS with high specificity (Parks et al, 1994). Cleavage by
TEV protease leaves one amino acid at the N-terminus of the protein of interest (Kapust
et al, 2002). The use of the TEV protease presented two problems. The first problem
was the low solubility of the protein in E. coli (Rachel and David, 1999). The second
problem was the auto-digestion of the protease yielding fragments of very low activity
(Lucast et al, 2001). We selected TEV protease developed by van den Berg et al, 2006.
The group used TEVS219N first created by Lucast et al, 2001. The single amino acid
change, S219N inhibited the auto-proteolysis and subsequent loss of activity of the
protease. The group then embarked on an accelerated mutagenesis scheme to develop a
mutated version of the TEV protease that had more solubility than the wild-type protein.
They developed a mutated TEV protease that was 5 times more soluble than the wild-type
but retained wild-type levels of proteolytic activity. The mutant TEVsh had 3 amino acid
changes from the wild-type (van den Berg et al, 2006).
Analysis of the crystal structure of both CcdB (Dao-Thi et al, 2004; Loris et al,
1999) and CAT (Andreeva et al, 2000) showed that a cleavage site between CcdB and
CAT might be hidden from the protease. To address this potential problem we adopted a
technique termed “Target-directed proteolysis at the ribosome” developed by Henrichs et
al, 2005. Henrichs et al. developed a technique for SecA inactivation by proteolysis in
vivo. Originally a technique called target-directed proteolysis allows complete
proteolytic inactivation of target proteins in vivo (Mondigler and Ehrmann, 1996). When
investigating Target-directed proteolysis sites in SecA, it was found that lack of complete
accessibility and protein folding caused the TEV cleavage site located downstream of
residue 195 to be incompletely cleaved (Mondigler et al, 1996). Henrichs et al. devised a
way to tether the TEV protease to the ribosome. The tethered TEV protease gained
access to the nascent polypeptide as it exited the ribosome before folding occurs. The
technique was successful at getting complete cleavage of the target protein (Henrichs et
al, 2005). The tethering motive was cloned from an E. coli trigger factor (tig). Previous
research showed that E. coli tig had a binding site on ribosomes (Hesterkamp et al, 1997).
The domain that retained the ribosomal tethering activity was the N terminal 144
residues. Henrichs et al, 2005 fused this domain to the N terminus of TEV protease and
the result was complete cleavage of SecA195. We adopted the same strategy and fused
tig144 to the TEVsh protease.
TEVsh protease gene was put under the control of a Plac/ara-1 promoter (Lutz et al,
1997), which was a synthetic fusion of a lac promoter and an arabinose promoter. This
synthetic promoter was regulated over a ~1800-fold range whereby derepression via
IPTG caused a ~100-fold induction. Activation with arabinose caused a 15-20-fold
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increase in promoter activity (thus both inducers lead to 1500-2000 fold activation) (Lutz
et al, 1997).
We prepared four clones, all of them had the fused gene ccdB/CAT under the
control of a PLtetO-1 promoter and all four clones had two TEV protease cleavage sites
(tev) flanking ccdB (The fusion gene is now tev-ccdB-tev-CAT). The differences between
the constructs were the origin of replication (pSC101* of 3-5 copies per cell and p15A of
30-50 copies per cell), the TEVsh protease, and the N terminal fusion to tig144 (Figure
5-6).
5.4.1

CONSTRUCTION OF THE REDESIGNED PLASMIDS

The constructs were built as separate pieces of DNA via PCR (Fusion gene,
Origin of replication p15A/pSC101*, and TEVsh/tig144TEVsh). Different pieces of
DNA were recombined sequentially into the destination plasmid pZS*24MCS to produce
the four target clones (Figure 5-6).
5.4.2

CONSTRUCTION OF THE FUSION GENE ccdB/CAT

The fused gene was created as follows: briefly ccdB and CAT were amplified
separately via Sequential PCR using Phusion™ High-Fidelity PCR (Finnzymes, MA).
Sequential PCR was carried out as mentioned before, the PCR primers were used to add
two tev sites (ENLFYQS), a PLtetO-1 promoter sequence (Lutz et al, 1997) and StuI
restriction site upstream of tev site 1 (Figure 5-7). The 15 base-overlaps the destination
plasmid were added to the 5’ end of the promoter. CAT was amplified via PCR with 15
base overlaps of the tev site 2 were added to the 5’ end of CAT and 15 base overlaps in
the destination plasmid were added to the 3’ end of CAT. The two PCR fragments were
gel purified and allowed to recombine using Infusion Advantage PCR cloning kit
(Clontech, CA). The recombination product (promoter-tev1-ccdB-tev2-CAT) was
amplified using appropriate primers and gel purified then used for recombination with the
target plasmid. The target plasmid was digested by AatII/EcoRI (NEB, MA) to remove
the plasmid’s own promoter, RBS, and MCS. Promoter-tev1-ccdB-tev2-CAT fusion was
recombined into the digested plasmid using Infusion Advantage PCR cloning (Clontech,
CA). Recombination product was transformed into electrocompetent One Shot ccdB
Survival Cells (Invitrogen, CA) and selected on kanamicin (25µg/ml) LB agar plates.
Clones that carried the insert were verified by PCR and sequencing. Table 2-1 lists
primers used for cloning under ccdB/CAT. Figure 5-8 shows the general scheme for
constructing all four clones.
5.4.3

EXCHANGING pSC101* WITH p15A

The pSC101* origin of replication was removed from the target plasmid via
double digestion with AvrII/SacII-HF (NEB, MA). The p15A origin of replication was
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Figure 5-6 Schematic of the four clones for testing ccdB regeneration from target
plasmid. Green ORF represent ccdB, blue ORF represent CAT, red ORF represent
TEVsh, tig144 is represented by gray ORFs, tetracycline promoter are represented by
black arrow heads and ara/lac promoters are represented by gray arrow heads, Origin of
replication is represented by black arrows.
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Figure 5-7 Modified fusion gene including tev sites.

Figure 5-8 Scheme for the construction of different target plasmids.
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amplified by PCR using pZA24MCS as a template. 15 base overlaps between the
amplicon and the ends of the digested plasmid were created in the same PCR.
Recombination, transformation and selection were carried out as mentioned before;
clones were selected and verified by PCR and DNA sequencing. At this stage we have
created two target plasmids (both have identical fusion genes) with a different origins of
replication (pSC101* & p15A). Table 2-1 lists primers used for this reaction under
“Origin Change”.
5.4.4

INSERTION OF TEVsh AND tig144TEVsh INTO THE TARGET PLASMID

Two different TEV protease constructs were created. The first was a fusion
between the TEVsh (van den Berg et al, 2006) and the promoter Plac/ara-1 (Lutz et al,
1997). As mentioned before, PCR was used to amplify each fragment. TEVsh amplified
from TH24 plasmid (gift from Dr Berglund) (van den Berg et al, 2006), and Plac/ara-1 was
amplified from pZS*24MCS. 15 base overlaps were created at the points of
recombination between both fragments i.e. the TEVsh amplicon included the translation
signals for the gene (RBS and first ATG). Recombination was carried out as described
previously. The promoter/TEVsh fusion was PCR amplified and gel purified. The
second TEV protease construct was composed of three pieces of DNA. One piece
represented the promoter Plac/ara-1 (Lutz et al, 1997), the second represented tig144 (from
the E. coli DH5α chromosome), and the third piece represented the TEVsh gene. PCR
was used to amplify each fragment and to create 15 base overlaps between all fragments
at the points where each fragment recombined with the other (Figure 5-8). An overlap
was created between the 3’end of the promoter and the 5’ end of tig144. Another overlap
was created between the 3’ end of tig144 and the 5’ end of TEVsh. Recombination was
carried out between all three DNA fragments, and the tripartite product was amplified by
appropriate PCR primers and the product was gel purified. Both TEVsh Constructs
carried 15 bases-overlap with the destination plasmid at each end. Both target plasmids
were linearized by AvrII digestion and then recombined with either of the TEVsh
constructs. Recombination products (Figure 5-6) were subsequently transformed,
selected and checked as before. (Table 2-1 has the list of primers under pBAD Cloning,
Tig144 Cloning, TEV for Tig144 Cloning, TEV for pBAD Cloning).
5.5

OPTIMIZING THE TARGET PLASMIDS

The target plasmid construction went through an optimization process. Pieces of
DNA were fused into the plasmid at different stages, as detailed in Figure 5-8.
Optimizations led to the emergence of problems that were not foreseen in the original
scheme and needed to be resolved in order for the target plasmid to be useful.
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5.5.1

StuI RESTRICTION SITE OVERLAPPING dcm METHYLASE SITE

We planned to use StuI site for insertion of the chlamydial library. The StuI
enzyme is sensitive to methylation. Methylation may take place because of an
overlapping dcm methylation site. A dcm methylation site overlapping StuI site was
created when tev site1 was added upstream of ccdB (AGGCCTGG the underlined
sequence is StuI site, the 2 extra Gs after the StuI site created CmCTGG which is a dcm
methylation site). To make the StuI site functional, methylation was prevented by
transforming target plasmids into the dcm deficient strain Bl21A1 E. coli (Invitrogen,
CA). Knowing that Bl21 was recA+/endA+ (Phue et al, 2008), we preformed an extra
washing step during plasmid preps to remove the excess nucleases (as recommended by
the manufacturer). BL21 was not used for long term storage of target plasmids.
5.5.2

REMOVAL OF StuI SITE

tig144 contained an StuI site at position Q9. In order to remove this site we
introduced a silent mutation into Q9 as follows: target plasmids were grown in dcm+ cells
(TOP10, Invitrogen) and plasmids were double-digested with StuI/SalI-HF (NEB, MA).
Under these conditions only a single StuI site (in tig144) was digested leaving the other
methylated StuI site intact. The double digest removed a 171 nt DNA fragment
overlapping the junction between the promoter and tig144. PCR was used to amplify this
171 nt fragment and to include 15 bases-overlap with digested plasmid ends. The reverse
primer was used to introduce a silent mutation into tig’s Q9. CAAggcct was mutated to
CAGggcct; the capital letter represented the mutated codon (encodes for Q) and the
underlined sequence represent the StuI site. The modified DNA fragment was
recombined into the target plasmid. Each recombination reaction was subsequently
transformed/selected and verified as before. Figure 5-9B shows 2 PCR amplicons
digested with StuI. Lane one represented the modified tig144, lane two represented
nonmodified tig144. The nonmodified tig144 was cleaved by StuI (small band) while the
modified tig144 resisted StuI digestion. (Table 2-1 has list of primers under “Tig144:
StuI Removal”).
5.5.3

ADDITION OF THE FIRST CODON OF ccdB AND MODIFICATION OF
tev SITE1

The translational signal of ccdB was removed during initial cloning of the fusion
gene. A chlamydial library inserted upstream of ccdB was planned to provide the
translational signal. After creating a tev cleavage site upstream of ccdB the first codon
was no longer the first ATG of ccdB gene. In order to make ccdB similar to the wild-type
gene we decided to insert the first codon of ccdB. The tev site1 in the fusion gene was
ENLFYQS. Cleavage occurred between Q/S leaving an S on 5’end of CcdB. The
polarity of Serine may have a detrimental effect on CcdB function. We decided to mutate
S to G as both S and G are strong cleavage sites for the TEV protease. The target
plasmid was digested with StuI/BmgBI. The double digestion removed 151 nt
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Figure 5-9 Functional analysis of target plasmids. Panel A shows sequencial nested PCR
that added ATG and tev cleavage sites to ccdB. Panel B shows StuI digestion of wildtype and modified tig144; lane 1 shows modified tig144 that is resistent to StuI digestion,
lane 2 shows wild-type tig144 sensitive to StuI digestion. Panel C shows Western blot
results of TEVsh expression (the membrane was probed by anti-V5 antibody). Lane 1
shows TEVsh lane 2 shows tig144TEVsh fusion. Panel D shows western blotting results
of reporter fusion protein expression (the fusion protein was probed by anti-CAT
antibody): lane 1 shows fusion protein not digested by TEVsh, lanes 2 to 5 show digested
fusion protein. The small size fragment represent CAT as seen in lanes 2 to 5, all four
target plasmids exhibit processed fusion protein. Panel E shows the effect of expressing
the fusion protein with TEVsh in ccdB sensitive E. coli. Turbid tubes represent clones
where TEVsh expression was inhibited (no inducers) while clear tubes represent clones
where TEVsh expression was induced.
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piece of DNA. overlapping ccdB 5’ half of the gene and tev site1. Sequential PCR was
used to amplify the 151 nt and reconstruct the tev site1 and insert ATG as codon 1 in
ccdB gene. The amplicon also had 15 bases-overlap with the digested plasmid. The
amplicon was gel purified, recombined into the plasmids transformed/selected and
verified as before. Figure 5-9A showed the results of the sequential PCR to create the
modified 151 nt.
5.6

FUNCTIONAL ANALYSIS OF TARGET PLASMIDS

Target plasmids were checked for expression of TEVsh and tig144TEVsh
proteases by Western blotting. TEVsh gene carried a C terminal V5 epitope tag and we
used antiV5 antibodies for detection. Samples were grown overnight under inducing
conditions (IPTG 1mM/Arabinose 0.2%). Cells were collected by centrifugation and
solubilized for gel electrophoresis. Electrophoresis and Western blotting were carried out
according to manufacture’s instructions (NuPage, Invitrogen). The membrane was
blocked overnight with nonfat dry milk and developed according to manufacturer’s
instructions. The primary antibody used was rabbit antiV5 antibody (Abgent, CA) and the
secondary antibody was HRP conjugated goat anti rabbit (Abcam, MA). Bands were
visualized by ECL reagent (Abcam, MA). Two bands were detected (Figure 5-9C).
Lanes 1 and 2 represented TEVsh (33.44 kDa) and tig144TEVsh (49.25 kDa)
respectively (the brackets represent the calculated molecular weights [MW]). The
Western blot showed significant agreement between the calculated MWs and the
observed ones.
To verify the expression and processing of the fusion protein, the four target
plasmids were compared to a plasmid that contained the fusion gene but did not contain
the TEVsh protease gene. The plasmids were digested with StuI. PCR amplified and gel
purified hctA leader sequence was recombined into the linearized plasmids; (Section
5.3.3 above). Recombined plasmids were transformed into ccdB resistant cells and
selected on Chloramphenicol (12.5µg/ml) LB agar plates. Positive clones were grown
overnight under inducing conditions (IPTG 1mM, Arabinose 0.2%) in LB broth. Cells
were collected by centrifugation and used for electrophoresis. Electrophoresis and
Western blotting were carried out according to manufacture’s instructions (NuPage,
Invitrogen). The membrane was blocked overnight with nonfat dry milk and developed
according to manufacture’s instructions. The primary antibody used was rabbit anti-CAT
(SIGMA, MS) and the secondary antibody was HRP conjugated goat anti-rabbit (Abcam,
MA). Immunoreactive proteins were visualized using an ECL procedure (Abcam, MA).
Target plasmids that did not express TEVsh protease showed the full length fusion
protein. The apparent size of the fusion protein agreed with the calculated size (~41.4 vs
43.5kDa respectively, Figure 5-9D upper panel lane 1). The four target plasmids (Figure
5-6) showed complete processing of the fusion protein. The complete processing of the
fusion protein was evident by the absence of the full length fusion-protein (upper panel
Figure 5-9D, lanes 2-5). Free CAT protein accumulated after digestion (lower panel
Figure 5-9D lanes 2-5) and its apparent size was in agreement with the calculated size
(>20.7 vs 25.49kDa). Longer exposure time (data not shown) showed detectable
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amounts of the unprocessed fusion protein in lanes 2 and 4 representing plasmids that
carry TEVsh/pSC101*, TEVsh/p15A.
Plasmids (TEVsh/p15A, tig144TEVsh/p15A) were selected for further analysis.
Both plasmids were transformed into BL21A1 cells (Invitrogen, CA). Transformed
Bl21AI cells were grown overnight in LB under inducing (IPTG 1mM, Arabinose 0.2%)
and non-inducing conditions. Figure 5-9E showed the results of a 24 hour culture.
Induced BL21 cells did not grow while uninduced cells showed growth. These results
confirmed that when TEVsh protein expression was induced the fusion protein was
processed and free CcdB protein accumulated. Free CcdB formation led to inactivation
of GyrA and E. coli growth was inhibited.
5.7
5.7.1

DISCUSSION

THE USE OF ccdB AS A REPORTER GENE

Initially we planned to use LacZ/CAT translational fusions to screen the
chlamydial library for ncRNA targets. Several investigators have used lacZ translational
fusions to analyze ncRNA/target interactions (Baker et al, 2007; De Lay and Gottesman,
2009; Mandin and Gottesman, 2009; Pulvermacher et al, 2009). We did a pilot
experiment where we inserted test sequence carrying translational signals upstream of the
LacZ fusion gene. The variability of the blue color (generated by X-gal) was significant
(data not shown). The fact that the main phenotype to determine ncRNA/target
interactions was variable for the same insert led us to switch to an alternative plan, LacZ
would however be used for quantification of potential interactions (β-galactosidase
assay). ccdB on the other hand, was used before in a limited number of applications.
Insertional inactivation of the gene was used to select clones with DNA inserts in the
gene (Gabant et al, 1997; Van Reeth et al, 1998). It was also used to screen for
mutations or inhibitors that interfere with protein splicing mediated by the RecA intein of
Mycobacterium tuberculosis. This screening procedure involved activation of the CcdB
protein by protein splicing, such that host cells survive in the presence of inducer only
when protein splicing was blocked (Lew and Paulus, 2002). CcdB is also used as a
general selection marker in the gateway system (Invitrogen, CA). Clones that fail to
undergo recombination and exchange the ccdB cassette with the insert do not survive
CcdB mediated killing. CcdB produced a criterion phenotype that is clear cut i.e. cell
death. A great deal is known about its function and it’s crystal structure has been
published (Dao-Thi et al, 2004; Dao-Thi et al, 1998; Loris et al, 1999). Moreover there
is an E. coli strain that is resistant to CcdB mediated killing (Bernard et al, 1992).
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5.7.2

CcdB LOSS OF FUNCTION AND REDSIGNING OF THE TARGET
PLASMID

ccdB fusions are not commonly used in molecular biology. The single fusion that
was reported was a lacZ N-terminal fusion to ccdB (Bernard, 1996; Gabant et al, 1997).
Personal communications with Paulus H (Lew et al, 2002) (Personal communications,
2009) revealed that CcdB lost its lethal effect when 25 or more amino acid residues were
fused to the N terminus. In this work we have presented the results of C terminal fusions.
We have tried N terminal fusions (data not shown), but this construct was very toxic and
we were not able to maintain an intact plasmid within the ccdB resistant cells. The
plasmid instability forced us to use C terminal fusions. CcdB in C-terminal fusion lost its
lethal effect. We shifted our plan to insert protease cleavage sites flanking ccdB so that
we regenerate a CcdB protein molecule similar to wild-type.
The loss of a lethal effect with CcdB-CAT fusions led us to propose that the C
terminal fusion to CcdB causes loss of activity. Bahassi et al. studied CcdB loss of
function mutants and found seven mutations in CcdB 3’ end that had no lethal effects.
The mutations were all in the last 3 amino acids of the molecule (Bahassi et al, 1995).
This finding suggested that the C terminal domain of the molecule was important for
function and that C terminal fusions might not function properly. Dao-Thi et al. analyzed
the crystal structure of CcdB bound to GyrA peptide (Dao-Thi et al, 2005) and showed
that CcdB W99 (CcdB has 102 amino acids total) interacted with GyrA462R. Mutations
in either of these two interacting amino acids led to loss of function for CcdB. Finally,
ccdB resistant cells have an identical mutation in GyrA (gyrAR462C).
In light of the previous argument, we reasoned that any deviation from wild-type
CcdB might be detrimental to its function. Dao-Thi et al. shown that CcdB functions as a
dimer. For dimerization to occur hydrophobic interactions between 6 methionines was
required (Dao-Thi et al, 2005). Although the first methionine was not included in the
interaction, we chose to re-insert M1. After TEV protease cleavage, the only residue that
was left on the N terminus was S (or G). We chose to mutate S to G to eliminate a
potential source of increased polarity in the region.
We designed four target plasmids. We reasoned that screening of chlamydial
libraries will result in cloning many chlamydial translational signals with wide range of
activities. The target plasmids therefore were designed with different copy number
controlling regions to cover the spectrum of translational strength. Two different origins
of replication were used. We also used two TEV protease constructs with different
proteolytic efficacy that allowed us to control the amount of available CcdB protein
within a cell. Although the Western blotting results does not show differences in efficacy
of TEV cleavage (Figure 5-9D, lanes 2-5), over exposure showed traces of undigested
fusion protein in clones carrying TEVsh (lane 2, 4). Total digestion of the fusion protein
was evident for clones having tig144TEVsh (lane 3, 5). This result is in complete
agreement with Henrichs et al, 2005.
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CHAPTER 6. CONCLUDING REMARKS
C. trachomatis D/UW-3/Cx expresses numerous ncRNAs that were initially
detected using an intergenic microarray and validated by Northern blotting analyses.
These include the subset of potential ncRNAs in this study which are potential cis-acting
(antisense), trans-acting, and riboswitches. We have shown that these ncRNAs have
distinct temporal expression patterns during the normal developmental cycle and several
appear to be processed. We have also shown that the expression of many ncRNAs was
altered during growth conditions that induce persistent growth, particularly IFN-γinduced persistence and carbenicillin-induced-persistence. We have mapped the ends of
these ncRNAs, a prerequisite for cloning and functional analysis of these molecules. We
have developed a system for testing cis-acting ncRNAs, and successfully used it for
verification of the proposed function of CTIG270. We have also developed a screening
system for trans-acting ncRNAs: a system based on positive/negative selection that is
fully functional in E. coli. We believe that this screening tool can also be used to screen
for ncRNA targets in other organisms.
Although these studies in C. trachomatis are primarily associated with the
discovery and validation phase for ncRNAs, they provide a strong basis for mechanistic
studies that may determine important regulatory roles for chlamydial ncRNAs in the
development cycle and the changes that occur during persistent growth of C. trachomatis.
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